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ABSTRACT OF THE DISSERTATION
AUTO-ANTIGENIC PROPERTIES OF THE SPLICEOSOME AS A MOLECULAR
TOOL FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS AND MIXED
CONNECTIVE TISSUE DISEASE PATIENTS
by
Annia Mesa
Florida International University, 2014
Miami, Florida
Professor DeEtta K. Mills, Major Professor
Systemic Lupus Erythematosus (SLE) and Mixed Connective Tissue Disease (MCTD)
are chronic, autoimmune disorders that target overlapping autoantigens and exhibit
similar clinical manifestations. Despite 40 years of research, a reliable biomarker capable
of diagnosing these syndromes has yet to be identified. Previous studies have confirmed
that components of the U1 small nuclear ribonucleoprotein complex (U1 snRNP) such as
U1A are 1000 fold more autoantigenic than any other nuclear component in SLE patients.
Based on these findings, I hypothesize that models derived from the U1 snRNP
autoantigenic properties could distinguish SLE from MCTD patients. To test this
hypothesis, 30 peptides corresponding to protein regions of the U1 snRNP were tested in
triplicates by indirect ELISA in sera from SLE or MCTD subjects. In addition laboratory
tests and clinical manifestations data from these patients were included and analyzed in
this investigation. Statistical classification methods as well as bioinformatics pattern
recognition strategy were employed to determine which combination, if any, of all the
variables included in this study provide the best segregation power for SLE and MCTD.
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The results confirmed that the IgM reactivity for U1 snRNP and U1A have the power to
significantly distinguish SLE from MTCD patients as well as identify kidney and lung
malfunctions for these subjects (p ≤ 0.05). Furthermore, the data analysis revealed eight
novel classification rules for the segregation of SLE and MCTD which are a better
classification tool than any of the currently available methods (p ≤ 0.05). Consequently,
the results derived from this study support that SLE and MCTD are indeed separate
disorders and pioneer the description of eight novel classification criteria capable of
significantly discerning between SLE and MCTD patients (p ≤ 0.05).
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I. INTRODUCTION
Autoimmune diseases develop when the immune system stops recognizing self
antigens and produces aberrant antibodies capable of developing equally over-reactive
responses to self as well as non-self antigens (Carroll, 2004). In general, individuals
diagnosed with these syndromes represent a heterogeneous population characterized by a
broad number of clinical manifestations that have unpredictable courses and often cannot
be associated with a unique autoimmune illness (Konforte et al., 2012). It is without
doubt that early and accurate recognition of these diseases could dictate the patient’s
treatment which in turn has the potential to improve the prognosis as well as reduce the
financial burden to the ill subject and family (Bodolay et al., 2007). Nevertheless, the
lack of recognition and categorization methods for autoimmune syndromes exhibiting
clinical and molecular features common in other well characterized autoimmune illnesses
has hampered diagnosis. As result, patients exhibiting characteristic overlapping clinical
manifestations observed in different autoimmune syndromes are often misdiagnosed and
go through years of clinical investigations and laboratory tests before obtaining the
accurate diagnosis (Adsay et al., 2005; Simao, 2010; Niţescu et al., 2011; Quinkler,
2012; Bertsias et al., 2013; Pena et al., 2013).
Mixed Connective Tissue Disease (MCTD) is one of the most commonly known
syndromes showing overlapping characteristics with other autoimmune disorders (Rebora
and Parodi, 1990; Aringer et al., 2005; Swanton and Isenberg, 2005; Nowicka-Sauer et
al., 2012). Sharp et al. (1972) initially described MCTD as a systemic autoimmune
disease characterized by elevated antibodies directed to subunits of the U1 small nuclear
ribonucloprotein particle (snRNP). Since then, diverse research groups defined it as a
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non-specific autoimmune syndrome with clinical and molecular features observed in
others syndromes such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
(SS), Rheumatoid Arthritis (RA) and Polymyositis (PM) (Mukerji and Hardin, 1993;
Egner, 2000; Haustein, 2005). The initial, but not always reliable, description of MCTD
as a benign disease that transforms into other well known autoimmune disorders has
limited its recognition during the study of SLE and other cohorts of autoimmune patients
(Sharp et al., 1972; Tan et al., 1982; Hochberg et al., 1997; Lundberg, 2005; Petri et al.,
2012; Shi et al., 2012). Recent studies have shown lung disease seems to be specifically
associated with MCTD but not SLE patients (Shirai et al., 2012; Watanabe et al., 2012;
Gunnarsson et al., 2013). By contrast, renal disorders have long been a characteristic
prevalent in SLE but not the MCTD population (Everett and Harrell, 1956; Natali et al.,
1972; Cavagna et al., 2013; Lin et al., 2013). The fact that independent studies have
described that SLE and MCTD patients are associated with malfunction of different
organs highlights the relevance of the recognition of MCTD concept as a clinical tool to
identify patients that could develop lung disease as oppose to kidney malfunction, for
example. Given that four different criteria sets currently coexist to identify MCTD
patients illustrates the significant challenges in uncovering clinical symptoms and/or
biomarkers that could be specifically associated with this autoimmune syndrome (Sharp,
1987; Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 1996).
During the past six decades, extensive studies have provided evidence to support
the following: first, MCTD exhibited a considerable number of overlapping features with
SLE making virtually impossible the segregation of some patients using currently
available classification criteria sets (Sharp et al., 1972; Tan et al., 1982; Amigues et al.,
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1996; Hochberg et al., 1997; Lundberg, 2005; Petri et al., 2012; Shi et al., 2012). Second,
the concept of MCTD has clinical relevance since malfunction of vital organs has been
reported to be prevalent in this syndrome when compared to SLE, for example (Everett
and Harrell, 1956; Natali et al., 1972; Shirai et al., 2012; Watanabe et al., 2012;
Gunnarsson et al., 2013). Third, new classification rules with significant power to
distinguish between SLE and MCTD patients need to be developed given that available
classification criteria sets were designed to identify either SLE or MCTD subjects but not
to segregate between these two autoimmune disorders (Sharp, 1987; Kasukawa et al,
1988; Kahn et al., 1991; Amigues et al., 1996; Hochberg et al., 1997; Petri et al., 2012).
Prompted by the clinical need for developing accurate methods to segregate between SLE
and MCTD patients, the present study explores auto-antigenic properties of the
spliceosome; a potential novel molecular tool for the discrimination of these two
autoimmune syndromes.
The spliceosome is a macromolecule composed of five distinguished RNA and
protein complexes known as U1 small nuclear ribonucleoprotein (U1 snRNP), U2
snRNP, U4 snRNP, U5 snRNP and U6 snRNP (Moore et al., 1993). All these snRNP
composites are arranged around the nascent pre-mRNA to remove introns and link exons
through the splicing reaction producing a final mature mRNA (Staley and Guthrie, 1998).
Earlier reports have confirmed the auto-antigenic properties of U1 snRNP in SLE and
MCTD patients. The U1 snRNP is the first spliceosomal subunit binding the pre-mRNA
and is composed of three specific U1 snRNP proteins (U1-70K, U1Ap and U1C) and
seven Smith (Sm) proteins (Pomeranz Krummel et al., 2009). Specifically, MCTD
subjects show prevalence of autoimmune response to U1 snRNP specific proteins
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(snRNP) while SLE individuals have a predominance response to Sm proteins (Luyckx et
al., 2005). Interestingly, the majority of previous analyses have focused on the autoantigenic properties of U1-70K and Sm proteins but not on U1A and U1C (McClain et
al., 2004; Luyckx et al., 2005). Likewise, the immunoglobulin G (IgG) immune response
for these and other nuclear antigens have been extensively documented in SLE and
MCTD patients while the potential role of other immunoglobulins (IgM, IgD, IgE and
IgA) has been limited (Zhang et al., 1995; Vlachoyiannopoulos et al., 1996; Witte et al.,
1998; Palafox Sanchez et al; 2009).
The present study will apply novel classification rules specifically designed for
SLE and MCTD discrimination by exploring the IgM response for 15 U1A and 15
additional U1 snRNP peptides, as well as analyzing the frequency and correlations of 183
clinical symptoms and biomarkers recorded in patients with these autoimmune
syndromes. The data analyses confirmed previous findings that the immune response for
U1A and U1 snRNP peptides mature from IgM to IgG in MCTD patients while SLE
subjects appear to retain IgM responses for these autoantigens. In addition, the results
revealed that models derived from the IgM reactivity for U1 snRNP and IgM anti-U1A
titers have the power to significantly segregate between SLE and MTCD patients as well
as identify kidney and lung malfunctions in subjects diagnosed with any of these two
illnesses (p ≤ 0.05), respectively. Furthermore, eight novel classification rules for the
segregation of SLE and MCTD were described and showed better classification power
than any of the currently available methods (p ≤ 0.05). Consequently, the results derived
from this study provide evidence to support the notion that SLE and MCTD are indeed
separate disorders while pioneer the description of eight novel classification criteria sets
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capable of discerning between SLE and MCTD patients (p ≤ 0.05). Recognizing that
validation of these findings is required, the data described have the potential to improve
the accurate clinical diagnosis of SLE and MCTD which in turn could increase the
patient’s prognosis and life quality.
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II. CHAPTER 1

Uncovering the IgM autoimmune response for U1Ap
in patients diagnosed with SLE or MCTD
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Introduction
The small nuclear ribonucleoprotein (snRNP) A (referred to here as “U1Ap”), in
combination with U1-70K and U1C, is a specific U1 RNP polypeptide that, along with
the U1-RNA and Sm proteins, forms an active U1 snRNP complex. The complex, in turn,
plays an essential role in pre-mRNA processing as a functional unit of the spliceosome
(Moore and Sharp, 1993). The spliceosomal composite is formed of two RNA
recognition motifs (RRM) located at the N- and C-terminal of the U1Ap and has been
reported to be conserved across the Eukaryote domain (Scherly et al., 1989; Chen et al.,
2007; Somarelli et al., 2010). The N-terminal RRM domain (RRM1) of U1Ap has been
extensively studied and has been shown to be necessary and sufficient to bind U1-RNA
via its stem loop II and facilitate the splicing process (Scherly et al., 1989, Jessen et al.,
1991, Somarelli et al., 2010). By contrast, little is known about the potential function of
the U1Ap C-terminal RRM domain (RRM2) despite similar characteristics to other RNA
binding domains including U1Ap RRM1 (Scherly et al., 1989, Tang and Rosbash, 1996).
The RRM2 of U1Ap exhibits unusual RNA binding properties since it does not bind to
U1, U2 or U5 stem loops or interact with random RNA sequences (Lu and Hall, 1995).
Autoimmune responses to U1 snRNP specific proteins, including U1Ap, have
been described in patients diagnosed with Systemic Lupus Erythematosus (SLE) and
Mixed Connective Tissue Disease (MCTD) (de Wildt et al., 1997; Faig and Lutz , 2003;
McClain et al., 2004; Sato et al., 2010). In some patient cohorts, anti-U1Ap responses
have been reported to be the first anti-U1-snRNP to develop (McClain et al., 2004).
Major organ involvement, including lung and kidney, are common in these individuals
(Gutsche et al., 2012; Braun-Moscovici et al., 2013). Though MCTD was described as a
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separate disorder (Sharp et al., 1972), there is much controversy regarding its
independent nature because of the great number of overlapping auto-antigens and clinical
manifestations shared with SLE (Rebora and Parodi, 1990; Swanton and Isenberg, 2005;
Nowicka-Sauer et al., 2012). Nevertheless, there are auto-antigens and clinical symptoms
that are more frequently exhibited in one disease group than the other. For example, SLE
patients show elevated immunoglobulin G (IgG) autoimmune responses to Sm proteins
while those with the autoimmune response directed to snRNP subunits are frequently
MCTD individuals (Luyckx et al., 2005). Clinically, kidney damage is more frequent in
SLE while lung malfunction is often observed in MCTD patients (De Clerck et al., 1989;
Sawai et al 1994; Yoshida et al., 1994; Watanabe et al., 2012). Previous studies have
described elevated IgG autoimmune response to U1Ap fragments in both SLE and
MCTD patients (Sato et al., 2010). In addition, Vlachoyiannopoulos et al. (1996) reported
that SLE but not MCTD patients showed a predominant immunoglobulin M (IgM)
response to snRNP subunits, including U1Ap. Furthermore, a recent study revealed that
U1Ap antigenicity against IgM could aid in the differentiation between these two
autoimmune disorders (Mesa et al., 2013).
The aim of the present study is to examine the IgM responses to U1Ap as a
molecular indicator to assess differences between SLE and MCTD, and to uncover
potential relevance of anti-U1Ap IgM reactivity in predicting organ targeting. To
accomplish the goal, a total of 17 U1Ap peptides encompassing most of the protein’s
sequence were monitored for their IgM antigenicity in sera from SLE and MCTD patients
with or without kidney and/or lung involvement. The results support previous findings
that SLE but not MCTD patients have prevalent IgM responses to U1Ap peptides

21

(Vlachoyiannopoulos et al., 1996, Mesa et al., 2013). Furthermore, IgM reactivity to
specific U1Ap fragments has potential to identify patients with kidney and lung
involvement with an accuracy of 72% and 71%, respectively (p ≤ 0.005). Consequently,
this investigation provides evidence to support that the IgM response to U1Ap peptides
could be employed as a predictive blood marker for kidney and lung damage in patients
diagnosed with either SLE or MCTD while contributing additional molecular evidence to
support the separate etiology of these autoimmune syndromes.

Materials and Methods
Patients recruitment
In this study, SLE (n = 56) and MCTD (n = 26) individuals presenting in either
outpatient or inpatient settings to the Division of Rheumatology at the University of
Miami Miller School of Medicine, consented to participate in research studies following
IRB-approved protocols between 2005 and 2010. Healthy individuals (n = 10) also
consenting to participate following IRB-approved guidelines were included as negative
controls. The American College of Rheumatology (ACR) classification criteria
(Hochberg et al., 1997) and the Alarcon Segovia criteria (Amigues et al., 1996) were used
to classify patients as having SLE and MCTD, respectively. In cases where both criteria
sets were satisfied, patient diagnoses were determined by the chart-documented
diagnoses of their clinical rheumatologists. All SLE and MCTD individuals included in
this investigation represent well characterized patients and have been subjects of previous
studies (Maldonado et al., 2006; Perkins et al., 2008; Somarelli et al., 2011, Mesa et al.,
2013).
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Medical records selection
Kidney involvement was defined following the American College of
Rheumatology SLE Classification Criteria’s renal criterion (Hochberg et al., 1997) and/or
renal biopsy. Sufficient information was available to make a determination in 70 of the
82 study patients.

Kidney involvement was present in 22 patients (19 SLE and 3

MCTD), and was absent in 48 patients (26 SLE and 22 MCTD). Lung disease was
designated to be present if pulmonary fibrosis was confirmed by chest X-ray or CT-scan,
or if pulmonary artery pressure by right heart catheterization or right ventricular systolic
pressure estimated by echocardiography meter exceeded 40 mmHg. Sufficient
information existed to make a determination about lung involvement in 52 patients, of
whom 26 patients had lung involvement (SLE = 18 and MCTD = 8) and 26 did not have
lung involvement (SLE = 20 and MCTD = 6). All the medical records were obtained
following the IRB protocols from University of Miami (IRB numbers: 20030724 and
20040286) and Florida International University (IRB number: 040308-00).

Selection and synthesis of U1Ap peptides
Auto-antigenic U1Ap peptides known to elicit an IgG autoimmune reaction in
SLE patients were obtained from literature review to be tested for IgM antigenicity
(Barakat et al., 1991; Arbuckle et al., 1998; Talken et al., 2001; Poole et al., 2009;
Somarelli et al., 2011). In addition, amino acid sequences corresponding to each of the
two RNA recognition motifs (RRMs) were included as peptides (P4 and P14, Table 1).
All peptides were commercially synthesized by BioMatik Corporation (Wilmington, DE,
USA) and purified by high performance liquid chromatography to ≥ 90% purity.
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Assessing IgM autoimmune response for U1A protein peptides
Whole blood from SLE (67 samples from 56 patients), MCTD (29 samples from
26 patients) and healthy (11 samples from 10 persons) individuals were obtained at the
moment of the recruitment and subsequent follow up visits, when applicable. Supernatant
serum from each patient was diluted 1:100 in phosphate buffered saline (1X PBS)
containing 10 mg/ml bovine serum albumin (BSA) and 0.5 mM phenylmethylsulphonyl
fluoride (PMSF) and subsequently stored at -80°C until tested. Diluted sample sera from
SLE, MCTD and healthy individuals were used to determine IgM reactivity for U1Ap
peptides via indirect-ELISA as previously described (Somarelli et al., 2011, Mesa et al.,
2013). Goat anti-human IgM horseradish peroxidase conjugated second antibody
(Southern Biotech, Birmingham, AL, USA) used at 1:2000 in BSA/PBS containing
0.05% Tween-20 (BSA/PBS-T). All ELISAs were performed in triplicate. Each ELISA
plate contained no peptide, no serum, no conjugate and no substrate controls. The optical
density (OD) value of the IgM anti-U1Ap titers in each patient was normalized by the
average IgM anti-U1Ap reactivity in the healthy group per peptide examined and
expressed as OD% following established methods (Muñoz-Paredes et al. 1999).

Generating and evaluating the U1Ap three-dimensional structure
A three-dimensional (3D) structural model of the full-length U1Ap (amino acids
1-282) was required to analyze the IgM anti-U1Ap titers given that currently the nuclear
magnetic resonance (NMR) structure for human U1Ap only includes residues 2 to 102
(Protein Data Bank (PDB) ID number: 1DZ5).

To generate a complete U1Ap 3D

structure, the U1Ap linear sequence was retrieved from the National Center for
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Biotechnology Information (NCBI) protein data bank (accession number: P09012) and
submitted to the I-TASSER server for protein structure and function prediction
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/) (Roy et al., 2010 and 2012). A total of
five models were generated for U1Ap with confidence scores (C-score) ranging from 2.19 to -3.98. Each of the U1Ap 3D models was superimposed on the U1Ap NMR 3D
structure (PDB ID: 1DZ5 containing 12 ensemble structures) using PyMOL (version
1.30) to obtain the most accurate structure possible. The best U1Ap model was selected
by finding the highest ratio of overlaid atoms to root mean square deviation (RMSD)
during super-positioning on each of the NMR structures in the ensemble. The I-TASSER
model 2 paired with ensemble structure 12 given that the assemble yielded the highest
ratio (565:1.679=318.0; detailed protocol for generating and evaluating U1Ap 3D models
is included in Appendix 1).

Mapping IgM response onto U1A protein 3D structure in SLE and MCTD patients
The observed IgM responses for U1Ap peptides in SLE and MCTD patients were
mapped independently onto the U1Ap 3D model. To construct the IgM reactivity
gradient for each peptide, the average value of the healthy group was adjusted to a
baseline of 0.5. Subsequently, the average IgM reactivity recorded in each of the SLE and
MCTD groups was expressed as a proportion relative to that baseline. Reactivity lower or
higher than the healthy patient averages per peptides resulted in proportional values
below or above 0.5, respectively. On the basis of the proportional value, each peptide was
mapped on a heat map with the scale ranging from blue for the lowest antigenicity, to
green, yellow, and finally red for the highest antigenicity.
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Statistical analysis
Significant differences in the average peptide antigenicity against IgM, in SLE
and MCTD patients were assessed by independent sample t-test. Correlation analyses
were performed to verify the IgM responses for U1Ap peptides were not correlated to
peptide size (p ≤ 0.05). A Chi-square test was employed to compare clinical and
laboratory categorical variables between SLE and MCTD patients. Spearman’s
correlation was employed to assess the association between IgM anti-U1Ap titers and
kidney or lung involvement. Binomial Logistic Regression (BLR) was used to assess
which combination of IgM reactivity for U1Ap peptides enhanced the discrimination
between patients presenting with kidney or lung involvement versus those lacking these
manifestations. Peptides that were found to be not significant in BLR analysis were not
included in subsequent tests. Receiving Operating Characteristics (ROC) curves were
used to confirm results obtained by BLR and determine the cut off values to ensure the
best sensitivity and specificity for kidney and lung models which were 0.5 and 0.6,
respectively. All the statistical analyses were performed using PASW statistical Data
Editor, version 18, with p ≤ 0.05 set as the standard for statistical inference for all the
tests executed.

Results
U1Ap peptides showed contrasting IgM antigenicity in SLE and MCTD patients
Indirect ELISAs were employed to assess IgM responses for U1Ap peptides in
sera from SLE, MCTD and healthy individuals. In general, SLE patients exhibited higher
IgM anti-U1Ap titers when compared to the healthy individuals (P1-P11 and P13, Figure
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1). By contrast, except for P5, P8 and P9, MCTD patients had lower IgM responses to
U1Ap peptides than healthy individuals (Figure 1). Interesting, IgM anti-U1Ap-P16 IgM
reactivity was significantly lower in both SLE and MCTD patients compared to healthy
controls (p ≤ 0.04) (Figure 1). SLE patients showed trends toward higher IgM reactivity
for U1Ap subunits than MCTD patients (P4, P6, P7, P10, P11 and P13 were the most
antigenic U1Ap fragments against IgM with 1.3 fold higher levels in SLE than MCTD
patients), but the differences were not significant (p > 0.05, Figure 1). Specifically, P7
and P17 represented the biggest (137%) and smallest (96%) differences between the SLE
and MCTD subsets.

Auto-antigenic IgM response is directed to non-RNA recognition domain regions of
U1Ap
To compare the IgM reactivity in the RNA recognition domain versus non-RNA
recognition domain fragments of U1Ap, the average peptide reactivity corresponding to
regions identified as RNA recognition motif (RRM) 1 (P1-P4), RRM2 (P14-17) and the
non-domain area (P4-P13) were calculated in SLE, MCTD and healthy populations.
Patients showed elevated IgM anti-U1Ap responses to non-domain areas of the U1Ap
(P5-P13) when compared to RRM1 (P1-P4) and RRM2 (P14-P17) (Figure 1). However,
only the SLE and not the MCTD patient subgroup exhibited significantly elevated
average IgM response to peptides in U1Ap non-domain regions when compared to the
average IgM reactivity for peptides covering RRM1 or RRM2 (p ≤ 0.003). The IgM
response to the U1Ap C-terminal end, which encompasses RMM2, was noticeably lower
in both SLE and MCTD patients than in control samples (Figure 1).

27

IgM derived U1Ap 3D epitope maps for SLE and MCTD patients
The IgM reactivity for each U1Ap peptide monitored in sera from SLE and
MCTD patients was used to create two independent epitope maps of U1Ap (Figure 2 and
detailed protocol in Appendix 1). In general, the IgM reactivity was not always directed
to exposed fragments of the U1Ap, given that superficial peptides appeared to have an
equal chance to be highly antigenic (P7 in SLE and P9 in MCTD) or not (P17 in SLE and
P4 in MCTD) (Figure 2). Likewise, different molecular structures like α-helices (P4), βsheets (P15) and loops (P8) seemed to elicit antigenic IgM responses to U1Ap. However,
β-sheets were the least antigenic of all three forms (P15 and P16 in Figure 2). When
comparing the SLE and MCTD subgroups, higher U1Ap IgM reactivity was directed to
superficial peptides with α-helical structure in both SLE (P7) and MCTD (P4) (Figure 2).
The lowest IgM responses were observed for peptides corresponding to exposed β-sheet
fragments of the U1Ap in both SLE and MCTD (e.g., P16 in both SLE and MCTD
patients in Figure 2).

IgM anti-U1Ap titers discriminate between patients with and without kidney involvement
The IgM responses to specific U1Ap peptides (P1, P2, P4, P5, P12, P15 and P16)
across the entire patient group significantly correlated with kidney involvement (p ≤
0.05). BLR analyses using all 17 U1Ap peptides confirmed that the combined IgM
reactivity for P2, P8, P11, P14, P15 and P17 (referred to as “U1Ap kidney model”)
represented the best predictor to identify patients with kidney disease (p ≤ 0.0001)
(Figure 3A). Specifically, ROC analysis confirmed that the U1Ap kidney model had
significant power (AUC = 0.828) to separate between patients with kidney and without
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kidney disease with 85% specificity, 45% sensitivity and 73% overall accuracy to
correctly categorize patients (p ≤ 0.005) (Figure 3B). Furthermore, the analyses revealed
that the capacity of the U1Ap kidney model to distinguish an SLE patient with or without
kidney disease was not significantly different than that observed in patients with MCTD
(p > 0.05).

IgM anti-U1Ap reactivity patterns and lung involvement
No anti-U1Ap peptide responses in univariate analyses were found to
significantly correlate with lung damage. However, BLR analysis revealed that the
combined IgM response to peptides P4, P9, P12 and P15 (the “U1Ap lung model”)
distinguished between patients with or without lung involvement similarly to the
performance of the kidney model above (AUC = 0.822) (Figure 4A). The overall
accuracy of the U1Ap lung model to classify patients was 79% with 81% sensitivity 77%
specificity (Figure 4B). As expected, the capacity of the U1Ap lung model to identify a
patient with or without lung disease was not significantly different when SLE or MCTD
subsets were contrasted.

Discussion
New markers that differ between SLE and MCTD patients are being described as
the understanding of these autoimmune syndromes increases (Sasaki et al., 2011; Lage et
al., 2012; Mesa et al., 2013; Jin et al., 2013). In the present study, the IgM reactivity for
peptides covering the full length of the U1Ap was explored to find potential novel U1Ap
antigens unique to either autoimmune disorder as well as to determine associations that
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might exist between IgM responses to U1Ap and organ targeting. The present
investigation reported differences between SLE and MCTD patients regarding their antiU1Ap responses, provided the first IgM derived epitope mapping of U1Ap for these
autoimmune disorders, and describe two patterns of IgM anti-U1Ap peptide reactivity
that are associated with kidney or lung disease.
The mapping of the IgM response onto the predicted 3D structure of the full
length U1Ap represented a unique approach to examine the behavior of the autoimmune
reaction for this protein in SLE and MCTD patients (Figure 2), especially since only the
U1Ap’s RRM1 NMR has been described (Varani et al., 2000). In concordance with a
previous report (McClain et al., 2004), U1Ap fragments that do not participate in protein
or RNA binding show the highest IgM antigenicity in both SLE and MCTD (P5-P13 in
Figures 1 and 2). Nevertheless, only SLE but not MCTD patients showed significant
differences when domains RRM1 and RRM2 were compared to non-domain areas (U1Ap
amino acids 87-206, p ≤ 0.05). The present study revealed that bound and unbound
region of U1Ap are capable of elicit an autoimmune response and therefore suggest that
unbound regions of U1Ap are not sufficient to elicit IgM antigenicity. Consequently,
other factor(s) like molecular mimicry from defective immune response to viral
infections described by Migliorini et al. (2005) could be essential in promoting antiU1Ap IgM responses in SLE but not MCTD patients. Contrary to the common believe
that antigenic fragments are located on superficial protein regions (McClain et al., 2004),
the data suggest that the IgM response to U1Ap does not appear to rely only on peptide
accessibility in the intact form of the protein. Consequently, it is reasonable to
hypothesize that the IgM response in SLE and MCTD patients could form prior to U1Ap
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reaching its native state or after deficient clearance of U1Ap apoptotic material like that
reported by the deleterious role of granzyme B in autoimmune diseases (Casciola-Rosen
et al., 1999; Mevorach, 2003). The fact that SLE and MCTD patients’ sera were unable
produce an autoimmune reaction for U1Ap RRM2 (P14-P17 in Figures 1 and 2) when
compared to U1Ap RRM1 (P1-P4) was not surprising given that RRM2 sequence differs
by 78% from that of RRM1 and its binding capacity has been shown to not resemble that
of a typical RNA binding protein (Lu and Hall, 1995). Taken all together, the 3D epitope
map not only allows for visualization of the IgM antigenicity of U1Ap fragments
determined by their location and molecular structure but also provides a basis to develop
a new hypothesis regarding the IgM response to U1Ap (Figure 2).
The binomial analysis revealed that the combined IgM reactivity of six U1Ap
peptides (P2, P8, P12, P14, P15 and P17) allowed the detection of kidney damage in
either SLE or MCTD patients with an overall accuracy of 72% (p ≤ 0.005) (Figure 3).
Interestingly, the power of the U1Ap kidney model did not significantly differ between
SLE and MCTD with kidney malfunction (p ≤ 0.05). The present study describes for the
first time an U1Ap model as a predictive serological biomarker for kidney disease.
However, levels of neutrophil gelatinase-associated lipocalin (NGAL), soluble vascular
cell adhesion molecule 1 (VCAM-1), Interleukin 6 (IL-6) and nucleosome have been
described as molecular determinants for kidney disease only for SLE but not reported for
MCTD patients (Yang et al., 2012; Pizarro et al., 2007; Brugos et al., 2012; Simón et al.,
2004). Currently, NGAL is considered the gold standard for the diagnosis and prognosis
of kidney injury with sensitivity (70.8%) and specificity (87.5%) in SLE patients (Haase
et al., 2009; Yang et al., 2012). Nevertheless, previous research derived from NGAL has
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not recognized the inclusion of MCTD patients therefore its power to detect kidney
disease in these unrecognized illness is unknown. Consequently, the proposed U1Ap
kidney model represents the only available blood marker for kidney disease for patients
diagnosed with either SLE or MCTD.
The combination of IgM reactivity for four U1Ap subunits (P4, P9, P12, and P15)
had significant power to identify patients with lung disease diagnosed with either SLE or
MCTD with an overall accuracy of 79% (p ≤ 0.002) (Figure 4). The U1Ap lung model
did not show significant difference in predicting lung damage when SLE and MCTD
were compared. However, lung biomarker homogeneity like the one observed in the
present study has been reported in patients suffering from autoimmune disorders
(Nishimaki et al., 1999). The proposed lung model is congruent with previous studies
given that auto-antigenicity against U1Ap has been associated with lung disease in SLE
and MCTD patients (Nishimaki et al., 1999; Bertoli et al., 2007; Cojocaru et al., 2011;
Lian et al., 2012) and has even been shown to be elevated in three different types of lung
cancer (Zhang et al., 2005 and 2008). Aside from these associations, no study has
recorded the predicted accuracy of these correlations and, as a result, chest radiography
has been the suggested method to diagnose lung injury (Levitt et al., 2013). Since
evidence of lung damage is reported in both of these autoimmune syndromes and
indicated to be the leading cause of mortalities in MCTD patients (Prakash, 1992;
Pehlivan and Inanc, 2010; Allen et al., 2012), the U1Ap lung model should be considered
as a new serological predictive factor for lung disease with the sensitivity and specificity
of 81% and 77%, respectively, in patients with either SLE or MCTD (Figure 5).
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In summary, the results are in agreement with previous studies given that there is
a prevalence of IgM anti-U1Ap reactivity in SLE but not MCTD patients (Figures 1). The
IgM derived U1Ap epitope map showed that peptide accessibility is not sufficient to
justify the contrasting autoimmune reactions observed in SLE and MCTD patients
(Figure 2) and the data suggests that molecular mimicry from previous infection and/or
deficient clearance of U1Ap apoptotic fragments are candidate factors for this difference.
Consequently, these findings constitute additional molecular evidence to support the
different etiology of these autoimmune disorders. Furthermore, for the first time, this
work described two serological biomarkers with the predicted capacity of 72% of
detecting kidney damage and 71% of identifying lung injury in patients diagnosed with
either SLE or MCTD (Figures 4 and 5). With acknowledgement that additional validation
of the U1Ap proposed models for identification of kidney and lung malfunction is
required, future research on biomarkers associated with organ malfunction in SLE
population should strongly consider the recognition of MCTD patients given the great
number of overlapping characteristics shared by these two autoimmune syndromes.

33

Table 1: U1A protein peptides characterization

Peptide
Number

Peptide
Position

Peptide Sequence

Peptide
length

Reference

P1

1–11

MAVPETRPNHT

11

Barakat et al. (1991)

P2

35–58

SQFGQILDILVSRSLKMRGQAFVI

24

Barakat et al. (1991)

P3

47–59

RSLKMRGQAFVIF

13

Arbuckle et al. (1998)

P4

60-95

KEVSSATNALRSMQGFPFYDKPMRIQYAKTDSDIIA

36

No previously tested

P5

96–103

KMKGTFVE

8

Poole et al. (2009)

P6

112-119

KPKSQETP

8

Somarelli et al. (2011)

P7

118–127

TPATKKAVQG

10

Poole et al. (2009)

P8

143–154

GMPPMTQAPRIM

12

Poole et al. (2009)

P9

159–178

GQPPYMPPPGMIPPPGLAPG

20

Poole et al. (2009)

P10

165–172

PPPGMIPP

8

Talken et al. (2001)

P11

178-185

GQIPPGAM

8

Somarelli et al. (2011)

P12

180–193

IPPGAMPPQQLMPG

14

Poole et al. (2009)

P13

196-203

PPAQPLSE

8

Somarelli et al. (2011)

P14

204-235

NPPNHILFLTNLPEETNELMLSMLFNQFPGFK

32

No previously tested

P15

236–242

EVRLVPGR

8

Poole et al. (2009)

P16

239–251

LVPGRHDIAFVEF

13

Arbuckle et al. (1998)

P17

257–282

AGAARDALQGFKITQNNAMKISFAKK

26

Barakat et al. (1991)
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Figures Legends
Figure 1: SLE but not MCTD patients show predominant IgM response to U1Ap
subunits. The diagram under U1A protein is a graphical representation of the linear
structure of this protein where RNA recognition motif 1 (RRM1) and 2 (RRM2) are
labeled. The amino acids covered by each of the peptides (P1-P17) are indicated under
peptide position. The red, blue and gray columns correspond to SLE (n = 56), MCTD (n
= 26) and healthy (n = 10) individuals, respectively. The lines on top of each column
represent the standard error.

Figure 2: U1A protein epitope map for IgM antigencity in SLE and MCTD patients.
The IgM optical density percentage (OD%) based on the healthy group IgM reactivity
obtained from SLE (top) and MCTD (bottom) patients was mapped onto the 3D structure
of U1A protein. The IgM antigenic scale is included at the bottom of the figure where
blue and red represent the lowest and highest IgM reactivity for U1A protein,
respectively. Gray areas on the SLE and MCTD epitope maps correspond to regions of
unknown IgM antigenicity since no peptide covers these specific fragments. The
rectangle embedded in the middle represents the U1A protein 3D structure where RNA
recognition motif 1 (RRM1) is labeled in red, RRM2 is colored in blue while the gray
fragments are regions free of RNA and protein interactions.

Figure 3: IgM reactivity for U1Ap is a candidate marker for kidney damage. The
observed IgM response to U1A protein (U1Ap) peptides was analyzed by binomial
logistic regression (BLR) to assess which peptide combination increase could
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significantly identify patients with kidney damage in either SLE or MCTD populations (p
≤ 0.05). The classification ability of each of these peptides and predicted models were
corroborated by receiving operating characteristic (ROC) curves analysis (p ≤ 0.05) A.
ROC curves revealed the power of U1A peptides in classifying patients with kidney
damage. In the graph, the peptides and predicted U1Ap kidney model are on the xaxis
while the area under the curve (AUC) resulting from ROC curves analysis is indicated on
the y axis. The larger the number, the higher the probability of identifying an individual
with kidney disease compared to a healthy individual. The lines on top of each column
correspond to standard deviation.

The p values ≤ 0.05, ≤ 0.001 and 0.0001 are

represented with one (*), two (**) or three (***) asterisks, respectively. B. Distribution
of patients with kidney damage based on the U1Ap kidney model. Patients with
evidence of kidney damage and healthy individuals are on the x axis while the predicted
probabilities obtained from BLR analysis are on the y axis. The black and white dots
indicate true positive (TP) and true negatives (TN) while the crosses represent either false
positives (FP) or false negatives (FN). A cut off value of 0.5 (from a range of 0 to 1) was
selected to allow equal chances to FP and FN (p ≤ 0.05).

Figure 4: IgM anti-U1Ap titers are potential biomarkers for lung damage. The IgM
reaction for U1A protein (U1Ap) peptides was analyzed by binomial logistic regression
(BLR) to uncover peptide combinations with power to discern between patients with lung
damage and healthy individuals in either SLE or MCTD populations (p ≤ 0.05). The
grouping capability of each of these peptides and predicted models were corroborated by
receiving operating characteristic (ROC) curves analysis (p ≤ 0.05) A. ROC curves
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showed the classification power of the U1Ap lung model. In the graph, the peptides and
predicted U1Ap lung model and area under the curve (AUC) resulting from ROC curves
analysis are on the x and y axes. The bigger the AUC, the higher the classification power
for lung disease. The lines on top of each column correspond to standard deviation. The
asterisks (***) represent p ≤ 0.0001. B. Segregation of patients with lung damage
utilizing the U1Ap lung model as classifier. In the plot, patients and predicted
probabilities of kidney damage are on the x and y axes. The black and white dots indicate
true positive (TP) and true negatives (TN), respectively, while the crosses represent either
false positives (FP) or false negatives (FN). A cut off value of 0.5 (from a range of 0 to 1)
was selected to allow equal chances to FP and FN (p ≤ 0.05).
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Figure 1: SLE but not MCTD patients show predominant IgM response to U1Ap
subunits
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Figure 2: U1A protein epitope map for IgM antigencity in SLE and MCTD patients.
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Figure 3: IgM reactivity for U1Ap is a candidate marker for kidney damage.
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Figure 4: IgM anti-U1Ap titers are potential biomarkers for lung damage.
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III. CHAPTER 2

Production of spliceosomal derived biomarkers for identification of SLE and MCTD
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Introduction
Systemic Lupus Erythematosus (SLE) and Mixed Connective Tissue Disease
(MCTD) are systemic autoimmune disorders with overlapping clinical manifestations
that possess aberrant immune responses against common auto-antigens (Zdrojewicz et al.,
1999; Egner 2000; Greidinger and Hoffman , 2001; Riemekasten and Hahn, 2005; Neogi
et al., 2006; Liu and Ahearn, 2009). Despite its description as an independent autoimmune disease (Sharp et al., 1972), the classification of MCTD as distinct from SLE
remains controversial because of the high number of common clinical features between
SLE and MCTD patients (López-Longo et al., 1994; Aringer et al., 2005; Swanton et al.,
2005; Venables, 2006; von Bierbrauer et al., 2008; Nowicka-Sauer et al., 2012).
Nevertheless, the concept of MCTD has been reported as a useful definition in clinical
practice (Zdrojewicz et al., 1999; Venables, 2006; von Bierbrauer et al., 2008; NowickaSauer et al., 2012), and clinical and serological features segregate the two illnesses
(Isenberg et al., 2007; Breda et al., 2010). The American College of Rheumatology
(ACR) has created universal classification parameters for SLE (Hochberg, 1997);
however, four different criteria sets exist for MCTD patients, with the Alarcόn-Segovia
criteria being the most widely accepted (Amigues et al., 1997).
Currently, there is no single test with sufficient specificity and sensitivity to
discriminate between SLE and MCTD, which has hampered the identification of MCTD
as a separate syndrome (Egner 2000; Reveille, 2004; Perkins et al., 2008; Liu and
Ahearn, 2009; Hoffman et al., 2012). A positive diagnosis by any set of criteria requires a
patient to exhibit at least four clinical symptoms and/or tests out of those included in each
list, which can take years to develop (Liu and Ahearn, 2009; Hoffman et al., 2012).
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Moreover, traditional laboratory tests are performed with numerous commercially
available kits that can vary in principle and cut-off values, which may alter the final
results and diagnoses (Egner 2000; Reveille, 2004; Mahler et al., 2005; Isenberg et al.,
2007; Chiaro et al., 2011). These and other factors complicate proper diagnosis of these
two closely related and overlapping illnesses.
Previous investigations have demonstrated that SLE and MCTD patients often
exhibit 1000-fold greater auto-reactivity to subunits of the U1 small nuclear
ribonucleoprotein particle (snRNP) than to any other cellular component (Hoet et al., 1993;
Vlachoyiannopoulos et al., 1996). The U1 snRNP is an RNA-protein complex that is
responsible for pre-mRNA processing and is composed of 10 proteins (U1-70K, U1A, U1C
and seven Smith antigen (Sm) proteins) (Luyckx et al., 2005; Mesa et al., 2008; Buratti et al.,
2010; Somarelli et al., 2010). In general, previous studies aimed at finding biomarkers for
SLE and MCTD have focused on IgG-specific responses to nuclear components, including
the U1 snRNP; however, some studies have revealed differential IgM reactivity for nuclear
components in SLE and MCTD patients (Zhang et al., 1995; Vlachoyiannopoulos et al.,
1996; Witte et al., 1998; Palafox Sánchez et al., 2009). Yet, the potential use of the IgM
response as a molecular tool to classify SLE and MCTD patients has not been fully
explored.
To determine whether SLE and MCTD represented distinct disorders and test
whether the two patient groups can be segregated, the IgG- and IgM-specific responses of
patients with SLE and MCTD and healthy individuals against 15 different U1 snRNP
peptides (named P1-15) were evaluated by indirect enzyme-linked immunosorbent assays
(ELISAs). Interestingly, higher IgG-specific reactivity for U1 snRNP peptides was
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observed

in individuals with SLE or MCTD compared to healthy individuals, but

elevated IgM responses in SLE patients compared to those with MCTD and healthy
adults. The IgM response to two peptides, P4 and P10 (P4/P10), exhibited 71.3%
accuracy in segregating between these two autoimmune disorders (p ≤ 0.05). In
summary, these data support the notion that SLE and MCTD are, indeed, distinct
disorders and highlight the potential clinical use of the IgM anti-U1 snRNP system as a
molecular tool to assist in the classification of SLE and MCTD patients.

Materials and Methods
Collection and preparation of sample sera
Sera were obtained from whole blood of 122 patients previously diagnosed with
SLE (n=81) or MCTD (n=41) and 31 healthy individuals. Samples were collected
following the Institutional Review Board (IRB) accepted protocols of the University of
Miami (IRB numbers: 200307-24 and 200402-86) and Florida International University
(IRB number: 040308-00). The SLE and MCTD patients (collectively refer as ill or
patient group) were clinically diagnosed according to the American College of
Rheumatology (ACR) criteria and the Alarcόn-Segovia criteria, respectively, along with
clinician judgment (Amigues et al., 1996; Hochberg, 1997). The laboratory tests
considered in the present study were commercially performed by Quest Diagnostic
Incorporated and their positive values are included in Table 3. Details of the flare or
remission period in these SLE and MCTD patients were not recorded at the moment of
whole blood collection and therefore disease activity for these SLE and MCTD patients is
not been considered in this study.
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Selection of U1 snRNP peptides
The U1 snRNP peptides included were previously reported in Somarelli et al.,
(2011) and commercially synthesized by BioMatik Corporation (Wilmington, DE, USA)
The observed IgM reactivity for each of the U1 snRNP peptides was ranked from most
(1) to least (15) antigenic for each disease state (Table 3).

Monitoring IgM reactivity for U1 snRNP peptides by indirect ELISAs
The indirect ELISA protocol employed to assess IgM reactivity for each peptide
and sample included was previously described (Somarelli et al., 2011). The average IgM
derived OD value for each peptide was normalized using the average OD value of the
healthy group per peptide examined and was expressed as OD% based on the following
formula (Muñoz-Paredes et al., 1999):
%=

× 100

where “ OD of sample in Px” is the average OD value of the sample group (SLE or
MCTD) and “ OD of control in Px” indicates the average OD of the control group
(healthy group) from each of the peptides included in this study (P1-P15). To evaluate the
relative reactivity contributed by IgM and IgG in SLE, MCTD and healthy populations,
the average OD values from IgG-specific ELISAs previously reported by Somarelli et al.,
(2011), which used the same samples and U1 snRNP peptides included in this study,
were re-analyzed and converted to OD% using the equation described above (MuñozParedes et al., 1999).
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Statistical analyses
Significant differences in IgG and IgM reactivity between patients (SLE and
MTCD) and healthy groups and between SLE and MCTD individuals for each of the
peptides was assessed using independent sample t-tests. Clinical tests and symptoms were
evaluated by independent sample t-tests (numerical data) or Chi (X) squared tests
(nominal data). Receiver Operating Characteristic (ROC) curves were generated with the
PASW software package (version 18). Forward binary logistic regression (BLR) analyses
using the IgM and IgG anti-U1 snRNP titers in ill (SLE and MCTD) and healthy individuals
as well as SLE and MCTD patients were performed with the PASW software package
(version 18). P-values ≤ 0.05 were considered statistically significant for all tests.
Correlations between each IgM anti-U1snRNP peptide titers and IgM anti-Rheumatoid
Factor (RF) antibody titers were performed using PASW software package (version 18),
however; since none of them were significantly correlated, they were not further considered
in this study.

Results
IgM anti-U1 snRNP reactivity is elevated in SLE but not MCTD patients
The IgM response to U1 snRNP peptides was monitored via indirect ELISAs and
reported as OD% (Figure 5A). IgM anti-U1 snRNP titers were significantly higher in the
SLE group than either the MCTD population or healthy individuals (p ≤ 0.05). In fact, in
many instances, IgM responses to U1 snRNP peptides in MCTD patients were equal to or
below those exhibited by healthy individuals (P3, P4 and P9-P15 in Figure 5A). The
discrimination capacity of IgM-anti-U1 snRNP peptide ELISAs was assessed by ROC
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curve analysis and indicates that IgM reactivity for P1 and P13 provides significant
power to classify SLE and MCTD patients; however, none of the IgM responses were
sufficient to discern SLE and MCTD from non-disease controls with statistical
significance (Figures 1C-D and Appendix 2).

SLE and MCTD patients exhibit an elevated IgG response for U1 snRNP peptides
As previous studies have reported (Fries et al., 1984; Nishimaki et al., 1999;
Lindorfer et al., 2001; Routsias et al., 2010; Ryu et al., 2011; Somarelli et al., 2011; ), the
IgG-mediated reactivity for each of the U1 snRNP peptides was significantly higher in
both SLE and MCTD populations than in the healthy group; however, IgG reactivity does
not differ between the two autoimmune disorders (Figure 5B). ROC curve analyses on
IgG anti-U1 snRNP titers per peptide ascertain their individual ability to discern between
patients (SLE and MCTD) and healthy individuals and between SLE and MCTD patients
(Figure 5C-D, respectively; and Appendix 2). As previously reported (Somarelli et al.,
2011), all but IgG anti-P2 responses were capable of significantly discriminating ill (SLE
and MCTD) and healthy individuals with IgG anti-P4 being the best (p ≤ 0.05); however,
none of the IgG anti-U1 snRNP titers had a statistically significant ability to classify SLE
and MTCD patients (Figure 5D).

Differential auto-immune responses and symptoms are observed in SLE and MCTD
patients
The results showed that SLE and MCTD patients exhibit significantly different
IgM anti-U1 snRNP reactivity (p ≤ 0.05) despite similar IgG-mediated antigenicity for
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the same peptides (Figures 1A-B). To further support the idea that SLE and MCTD
represent distinct auto-immune illnesses, statistical analysis of 42 standard laboratory
tests were performed with blood samples from the SLE and MCTD patient cohort. These
analyses revealed that 11 out of the 42 clinical tests were significantly different in SLE
and MCTD patients (p ≤ 0.05) (Table 2). Specifically, differences were observed in tests
designed to detect nuclear auto-antigens (RNP, Sm, Scl70, dsDNA, elevated DNA), renal
function (creatine phosphokinase levels, renal proteinuria, renal hematuria) and immune
system components (C3 and C4 complement levels) (p ≤ 0.05). These findings support
the idea that SLE and MCTD represent distinct autoimmune manifestations, with specific
antigenic targets and antibody class reactivities.
Similarly, statistical assessment of 40 clinical symptoms from patients in the SLE
and MCTD cohort indicated that 16 out of the 40 clinical characteristics evaluated were
significantly different between SLE and MCTD patients (Table 4). Most of the
significantly different clinical manifestations involved the skin and joints of these
patients; however, the data also confirmed that neuropsychiatric disorders and problems
in the circulatory system were also significantly different between the two groups. Once
again, the fact that clinical symptoms differ in SLE and MCTD populations supports the
hypothesis that these maladies may be clinically distinct.

Antibody class reactivities for U1 snRNP peptides segregate among SLE, MCTD and
healthy individuals
The IgM and IgG responses for all U1 snRNP peptides were combined in a BLR
to determine which peptide and auto-antibody combinations might provide the highest
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segregation between patient (SLE and MCTD) and healthy populations. These analyses
revealed that the combined IgG-specific response for P2, P4, P5, P10 and P13 has the
greatest capacity to discern between sick and healthy individuals with an overall accuracy of
94% (p ≤ 0.05) (Figure 6A) where the probability of correctly predicting a patient with
either SLE or MCTD is higher than that for correctly predicting a healthy individual
(96.7% and 83.9%, respectively).
Additional BLRs were performed with the individual IgG and IgM reactivities for
each U1 snRNP peptide to assess which peptide and Ig class combination significantly
discriminates between SLE and MCTD patients. These analyses indicated that only the
combined IgM response for P4 (U1C) and P10 (U1A) significantly discriminate between
SLE and MCTD patients, with an overall accuracy of 71.3% (p ≤ 0.05) (Figure 6B).
Remarkably, most of the classification power derives from the proper classification of
SLE patients (95.1%) rather than proper grouping of MCTD patients (24.4%) (Figure
6B). Consequently, the data demonstrate that by first combining the IgG reactivity for P2,
P4, P5 and P10 and then the titers for IgM anti-P4/P10, an overall accuracy of 73.9% at
discriminating among SLE, MCTD and healthy groups can be achieved.

Comparing the power of IgM anti-P4/P10 with conventional clinical tests
To determine the classification power of the proposed IgM-specific P4/P10
ELISA-based system, ROC curves were used to compare this system with eight
conventional clinical tests. The individual IgM reactivities for P1 and P13 were also
included in the ROC curves analyses because they discriminate between SLE and MCTD
(Figure 5D). The 11 laboratory tests that significantly differ between SLE and MCTD
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patients were performed only in a small portion of each sub-population (Table 2). Not all
tests could be analyzed as result of the reduced sample size. Instead, eight of the most
frequently-used laboratory tests that are part of the classification criteria to diagnose SLE
or MCTD were included in the ROC curve analysis (FANA titers, dsDNA ELISA,
elevated serum DNA titers and positive results for RNP, Sm, SSA, SSB and Scl-70)
(Egner, 2000; Mahler et al., 2005; Isenberg et al., 2007; Breda et al., 2010). When using
the subset of individuals for whom clinical test results were available (SLE = 59 and
MCTD = 24), the IgM anti-P4/P10 titers and IgM anti-P1 reactivity displayed the greatest
discrimination capacity to classify SLE and MCTD patients (p ≤ 0.05) (Figure 7 and
Appendix 2). The ROC curves confirmed that among the conventional tests evaluated,
elevated DNA and positive results for Sm are the third and fourth best at significantly
segregating SLE and MCTD (p ≤ 0.05).

Improving the discriminatory capacity of IgM anti-P4/P10 titers
The BLR analyses were performed to assess whether the combination of the IgM
anti-P4/P10 system and any of the eight laboratory tests employed to diagnose SLE or
MCTD (FANA titers, dsDNA ELISA, elevated serum DNA titers and positive results for
RNP, Sm, SSA, SSB and SCL-70)4;

15-16; 21-22

might provide greater capacity to

distinguish between these syndromes. The individual IgM reactivities for P1 and P13
were considered in this BLR analysis because they showed a significant ability to classify
SLE and MCTD patients (p ≤ 0.05) (Figure 5D). The BLR analyses indicated that the
combination of the IgM-based reactivity for P4/P10 and an elevated DNA assay represent
the best combination of variables to segregate SLE from MCTD when compared with
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IgM anti-P4/P10, -P1, or-P13 and any single laboratory test examined (p ≤ 0.0001)
(Figure 7 and Appendix 2). None of the other clinical test combinations improved the
power of discrimination between SLE and MCTD patients over that exhibited by the
individual tests alone (p ≤ 0.05). The analyses also suggest that, when combined with the
standard elevated DNA test, the IgM response against P4/P10 may be useful in enhancing
the current segregation of SLE from MCTD.

Discussion
Despite the fact that MCTD was described as a distinct rheumatic syndrome in
1972 (Sharp et al., 1972), placement of this disorder as a separate auto-immune illness
remains controversial. Opinions are divided regarding classification of MCTD as a
separate malady due to the number of auto-antigens and clinical symptoms that show
overlap with SLE (López-Longo et al., 1994; Aringer et al., 2005; Swanton et al., 2005;
Venables, 2006; von Bierbrauer et al., 2008; Nowicka-Sauer et al., 2012). The immune
responses of SLE and MCTD patients for overlapping ‘self’ antigens coupled with the
diversity of commercially available clinical tests with differing protocols, reagents and
cut-off values have impeded the development of standard and uniform assays to segregate
these syndromes (Egner, 2000; Mahler et al., 2005; Neogi et al., 2006; Liu and Ahearn,
2009). With the exception of a few studies (Vlachoyiannopoulos et al., 1996; Zhang et al.,
1995; Witte et al., 1998; Palafox Sánchez et al., 2009), most investigations have focused
on IgG-mediated reactivity toward specific antigens as potential molecular tools to
differentiate between SLE and MCTD patients (Fries et al., 1984; Lindorfer et al., 2001;
Routsias et al., 2010; Ryu et al., 2011). Given that SLE and MCTD patients are
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characterized by elevated blood titers of multiple Ig classes, including IgM (Pollar and
Tan. 1985; Kingsmore et al., 1989; Vlachoyiannopoulos et al., 1996), it was hypothesized
that IgM responses to a number of U1 snRNP peptides may allow us to increase the
present discrimination between SLE and MCTD and provide additional molecular
evidence to claim the independent nature of these two disorders.
The data indicate that the combined IgM reactivity for fragments of U1C (P4) and
U1A (P10) is capable of classifying SLE and MCTD patients with an accuracy of 71.3%
(Figure 6B), a value higher than previously reported peptide-based immunoassays that
have been used to segregate these disorders (Mahler et al., 2005). These findings are in
concordance with previous reports, which revealed a preponderance of IgM anti-U1
snRNP antibodies in SLE, but not MCTD patients (Zhang et al., 1995;
Vlachoyiannopoulos et al., 1996). Therefore, the present work is congruent with prior
investigations and demonstrates the potential utility of differential Ig class responses as a
classification tool for SLE and MCTD.

The current work also provides molecular

evidence to support the distinct etiology of these syndromes.
The binomial analyses identified combinations of laboratory tests and/or peptide
reactivities that significantly discern between these maladies. Interestingly, the IgM antiP4/P10 ELISA-based system provided the greatest capacity to segregate between SLE
and MCTD disorders and eight other conventional laboratory tests (p ≤ 0.0001) (Figure
7). Additionally, we revealed that the combination of IgM anti-P4/P10 antigenicity with
the elevated DNA test segregated 79.8% of SLE and MCTD patients, even in the smaller
subset of patients for whom clinical test results were available (n = 59 for SLE and n = 24
for MCTD) (Figure 7). It is not surprising that the dsDNA test contributes to the
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differentiation of these diseases given that antibodies against DNA have been detected in
approximately 70% of SLE patients and shows 95% specificity for this disorder
(Reveille, 2004; Breda et al., 2010). Yet, the fact that the dsDNA test alone exhibits a
lower ability to segregate SLE and MCTD patients (66.4%) than the IgM anti-P4/P10
system (73.1%), indicates the significant contribution of this ELISA-based system in
discerning between these two maladies (Figure 7).
A total of 16 out of 40 clinical manifestations studied significantly differ between
SLE and MCTD patients (Table 4). On average, MCTD patients exhibited hand/joint
swelling and muscle weakness with 25% higher frequency than SLE patients. Similarly,
malar and discoid rashes were found to be more prevalent in the SLE than the MCTD
group (46% and 10% versus 13% and 0%, respectively). These findings are in
concordance with previous studies that reported these clinical manifestations as key
features in SLE or MCTD patients (Perkins et al., 2008; Hoffman et al., 2010). Evidence
of mental illness was also found to be 32% higher in MCTD than SLE patients. Although
selection bias of the clinicians diagnosing these disorders cannot be ruled out, the results
obtained from a subset of SLE and MCTD patients suggest that the immune response of
SLE patients seems to be directed to skin areas on the face while those suffering from
MCTD appear to develop a more systemic immune response that attacks the skin, joints
and muscles throughout various parts of the body. Furthermore, these findings highlight
specific clinical manifestations that appear to differ between SLE and MCTD patients
and should be considered as clinical evidence that they may be distinct diseases.
Overall, this study further highlights the current challenges in developing quantitative
tests for the classification of SLE and MCTD and therefore the recognition of MCTD as
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a separate entity (Egner, 2000; Mahler et al., 2005; Neogi et al., 2006; Liu and Ahearn,
2009). Here, a novel approach based on differential antibody class (IgM and IgG)
responses has been described as a mechanism to discriminate between SLE and MCTD
patients with better accuracy than conventional laboratory tests currently employed as
part of the classification criteria to diagnose these syndromes. In addition, the data
revealed contrasting frequencies of clinical symptoms characterizing these auto-immune
syndromes whereby SLE patients showed a concentrated auto-immune manifestation
directed to skin areas on the face while those suffering from MCTD developed more
systemic immune responses that attack the skin, joints and muscles throughout various
parts of the body. Consequently, these results provide further evidence to support the
fact that there are molecular and clinical aspects of SLE and MCTD to indicate that
these diseases are, indeed, two distinct autoimmune syndromes.
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Table 2: Clinical tests evaluated in SLE and MCTD patients

SLE / MCTD specific

Fluorescence antinuclear Abs titers
Fluorescence antinuclear Abs pattern
IgG anticardiolipin positive
IgM anticardiolipin positive
Rheumatoid factor titer by latex
IgM anti-rheumatoid factor Abs by ELISA
IgM anti-rheumatoid factor Abs titer
RNP positive
Sm positive
SSA positive
SSB positive
SCL 70 positive
Elevated serum DNA titer
Anti-dsDNA positive
IgG anti U1-70K Abs*
IgG anti SmB/B' Abs*
IgG anti SmD Abs*
Anemia
Hemolytic anemia
White blood count
Leukopenia
Lymphopenia
Thrombocytopenia
Thrombocytosis
Creatine phosphokinase positive
Creatine phosphokinase elevated
Serum creatinine
Renal cellular cast
Renal proteinuria
Renal hematuria
C reactive protein
Elevated C reactive protein
Low C3 complement
C3 complement level
Low C4 complement
C4 complement level
Erythrocyte sedimentation rate
Elevated erythrocyte sedimentation rate

General

Clinical test name

IgG anti-rheumatoid factor Abs
IgG anti-rheumatoid factor Abs titer
Immunoglobulin isotypes for RF factor
Lymphocyte absolute value

SLE

MCTD

Positive

Total

Positive

Total

P
value

76.56%
86.30%
23.53%
6.06%
8.33%
41.86%
20.93%
84.00%
60.27%
58.11%
21.62%
1.45%
64.10%
49.35%
37.84%
44.12%
73.53%
25.00%
3.23%
8.77%
11.54%
36.71%
10.13%
5.13%
91.07%
7.02%
10.53%
10.67%
40.85%
18.92%
20.83%
23.61%
41.77%
56.96%
48.10%
44.30%
57.89%
56.48%

64
73
68
66
12
43
43
75
73
74
74
69
78
77
37
34
34
80
62
57
78
79
79
78
56
57
76
75
71
74
72
72
79
79
79
79
79
76

90.63%
85.71%
23.81
18.18%
20.00%
38.10%
23.81%
100%
28.21%
47.22%
11.11%
16.13%
29.73%
27.03%
55.00%
50.00%
63.16%
22.50%
8.33%
6.06%
12.50%
42.5%
2.50%
2.56%
74.29%
25.71%
5.26%
2.56%
13.51%
2.70%
18.18%
20.59%
15.00%
82.50%
30.77%
69.23%
52.27%
55.00%

32
35
21
22
5
21
21
40
39
36
36
31
37
37
20
20
19
40
12
33
40
40
40
39
35
35
38
39
37
37
33
34
40
40
39
39
40
40

0.3860
0.4430
0.8480
0.0870
0.0870
0.8480
0.9040
0.0080
0.0010
0.2820
0.1800
0.0040
0.0010
0.0010
0.2130
0.7700
0.7260
0.7630
0.4120
0.2780
0.8780
0.5400
0.1370
0.5180
0.4770
0.0120
0.4500
0.1280
0.0040
0.0180
0.4850
0.7290
0.0030
0.0001
0.0730
0.0001
0.8530
0.8710

41.86%
41.86%
79.07%
74.14%

43
43
43
58

42.86%
38.10%
76.19%
75.86%

21
21
21
29

0.9400
0.8480
0.5300
0.3460
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Table 3: Overview of U1 snRNP peptides used in the study

Peptide
number

U1 snRNP
protein

Peptideregion
(amino acid range)

Peptide
sequence

1†*

U1A

196-203

PPAQPLSE

2†*

Sm E

63-70

EIHSKTKS

3†*

Sm F

46-53

NTEEYIDG

4†*

U1C

90-97

5*

U1-70K

6†*

Observed IgM
reactivity ranked
SLE
MCTD
1
6
3

2

12

9

GMMPAPHM

11

8

337-344

PDGPDGPE

6

4

Sm B

83-90

EGPPPKDT

2

3

7†*

Sm G

1-8

MSKAHPPE

5

5

8†*

Sm D3

20-27

CETNTGEV

4

1

9†*

Sm F

77-84

EEEEDGEM

9

12

10†*

U1A

112-119

KPKSQETP

13

13

11†*

Sm D2

14-21

EELQKREE

10

11

12†*

Sm D1

22-29

GTQVHGTI

8

10

13†*

U1A

178-185

GQIPPGAM

14

14

14†*

U1-70K

325-332

APPDDGPP

15

15

15†*

U1C

66-73

PFSAPPPA

7

7

The peptide designation, region and sequences as well as the U1 snRNP protein column displayed in this table
(first four columns) were previously published by Somarelli et al. (2011). The observed IgM antigenicity
(columns 5 and 6, from left to right) was ranked from 1 to 15 where “1” represents the peptide with the highest
IgM antigenicity and “15” indicates the peptide with the lowest IgM antigenicity. Daggers (†) indicate IgM
peptide antigenicities that significantly differ between SLE and MCTD patients while the asterisks (*) represent
IgG reactivities for U1 snRNP peptides that significantly differ between ill (SLE and MCTD) and healthy
individuals (p ≤ 0.05).
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Table 4: List of clinical symptoms observed in SLE and MCTD

Clinical symptom name
Skin telangiectasia
Skin nasal/oral ulcers
Raynaud’s syndrome
History of hand swelling
Observed hand swelling
Acrosclerosis
Skin digital pitting
Proximal scleroderma
Skin alopecia
Malar rash
Discoid rash
Skin rash
Skin photosensitivity
Skin calcinosis
Sicca, xerophthalmia and
xerostomia
Erosive inflammatory arthritis

SLE
MCTD
Positive Total Positive Total
5%
79
15%
40
29%
79
23%
39
53%
80
85%
40
41%
81
61%
41
19%
81
39%
41
4%
80
26%
38
8%
80
8%
39
3%
79
0%
39
58%
80
72%
39
46%
78
13%
39
10%
78
0%
39
33%
78
38%
39

p-value
0.0650
0.4880
0.0001
0.0120
0.0140
0.0001
0.9700
0.3160
0.1310
0.0001
0.0380
0.5840

57%
1%

76
79

58%
5%

38
38

0.8940
0.2000

49%

81

66%

41

0.1330

43%

23

45%

20

0.9200

Lymphadenopathy

24%

79

20%

40

0.6180

Fever
Proximal muscle weakness

22%
29%

78
76

15%
49%

40
39

0.7780
0.0360

Myositis

6%

79

27%

33

0.0020

Myalgia

54%

80

48%

40

0.8970

Morning stiffness

53%

73

64%

36

0.3000

42%

78

63%

40

0.0380

35%
29%
27%
6%
82%
31%
4%

79
78
78
77
79
77
80

69%
63%
64%
10%
84%
28%
0%

39
40
39
40
38
40
40

0.0010
0.0010
0.0001
0.5000
0.7950
0.6810
0.2150

Swelling of three or more
joints
Joint tenderness
Joint swelling
Symmetric swelling
Rheumatoid nodule
Arthralgia
Neuropathy
Seizure
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Table 4, continuation

Clinical symptom name
Psychosis
Neuropsychiatric disorder
Hypomotility in cine
deglutition esophageal
Pulmonary fibrosis
Pleuritic pain or rubbing heard
Pericarditis
Avascular necrosis
Clotting
Myocardial infarction
Stroke

SLE
Positive Total
3%
79
19%
78

MCTD
Positive Total
0%
39
51%
39

p-value
0.3160
0.0001

41%

78

58%

40

0.0890

22%
37%
30%
3%
1%
0%
6%

45
78
73
74
75
73
81

23%
23%
18%
0%
12%
11%
2%

26
39
39
33
34
35
41

0.6330
0.1250
0.1610
0.3040
0.0160
0.0030
0.3570
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Figure legends
Figure 5: Contrasting IgM-specific anti-U1 snRNP peptide responses observed in
SLE and MCTD patients. (A) and (B) represent the average percent optical density
(OD%) values for the IgM class and IgG classes, respectively. Peptide number and OD%
are on the x and y axes, respectively. The black, gray and white bars symbolize the
average OD% of SLE, MCTD and healthy groups, respectively. (†) and (*) indicate
significantly different OD% between SLE and MCTD as well as patients and healthy
populations, respectively (p ≤ 0.05). (C) and (D) correspond to the area under the curve
(AUC), derived from ROC curves, for ill (SLE and MCTD) vs. healthy individuals as
well as SLE vs. MCTD patients, respectively. Peptide number per Ig class and their AUC
values are indicated on the x and y axes, respectively. () and () symbolize
significantly different AUC between patients and healthy individuals as well as SLE and
MCTD patients, respectively (p ≤ 0.05). The dotted lines in C and D indicate the cut-off
value (0.5). Black bars in all graphs represent standard error of the mean.

Figure 6: Identification of a two-step ELISA system for classification of SLE,
MCTD and healthy individuals. (A) The combination of IgG-mediated antiP2/P4/P5/P10/P13 provides the best segregation between SLE and MCTD vs non-disease
controls. The distribution of ill (SLE and MCTD) and healthy individuals and the
predicted combined IgG-mediated reactivity are represented on the x and y axes,
respectively. Gray and white circles indicate true positives (TP). (B) Combined IgManti-P4/P10 can classify SLE and MCTD patients. The distribution of SLE and MCTD
patients’ combined IgM anti-P4/P10 predicted values are on the x and y axes,
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respectively. Black and gray diamonds indicate true positive (TP) samples for SLE and
MCTD patients, respectively. The crosses represent false negatives (FN) or false
positives (FP). Predicted values were obtained using binomial logistic regression (BLR)
with a cut-off of 0.5 (p ≤ 0.05).

Figure 7: Area under the curve analysis reveals the classification power of IgM antiP4/P10. Receiver operating characteristic (ROC) curves were generated using peptide
antigenicities or laboratory tests. The columns in the graph represent the area under the
curve (AUC) in the y axis for each variable tested. The bars on top of each column
indicate standard error of the mean. FANA titers, dsDNA, ↑DNA (elevated serum DNA)
and positive results for RNP, Sm, SSA, SSB and SCL are clinical tests used during SLE
and MCTD diagnosis. The “IgM anti-P4/P10” indicates the combined IgM anti-P4/P10
titer while “IgM anti-P4/P10 + ↑DNA” represents the combination of the IgM antiP4/P10 ELISA and the elevated DNA assay. The “*” and “**” indicate significant
differences in classifying SLE and MCTD with p values of ≤ 0.05 and ≤ 0.0001,
respectively.
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Figure 5: Contrasting IgM-specific anti-U1 snRNP peptide responses observed in
SLE and MCTD patients
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IgG

Figure 6: Identification of a two-step ELISA system for classification of SLE,
MCTD and healthy individuals.

(A) IgG anti-P2/P4/P5/P10/P13 response

(B) IgM anti-P4/P10 reactivity discerns

segregates ill and healthy individuals

between SLE and MCTD patients
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Figure 7: Area under the curve analysis reveals the classification power of IgM antiP4/P10
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IV. CHAPTER 3

Developing novel classification rules customized to distinguishing
between SLE and MCTD patients
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Introduction
Mixed Connective Tissue Disease (MCTD), also known as Sharp’s syndrome,
was first described in 1972 as an autoimmune disease characterized by high titers of
antibodies to U1 small nuclear ribonucleoprotein particle (snRNP) (Sharp et al., 1972).
Since then, the concept of MCTD as a distinct clinical entity has been challenged due to
the number of common characteristics share mainly with Systemic Lupus Erythematosus
(SLE) (Aringer et al., 2005; Nowicka-Sauer et al., 2012) and less often with other
autoimmune syndromes such as Polymyositis (PM), Systemic Sclerosis (SS) and
Rheumatoid Arthritis (RA) (Mukerji and Hardin, 1993; Egner, 2000; Haustein, 2005).
Even though the Alarcόn-Segovia criteria is currently the most accepted criteria for
MCTD, the fact that four different MCTD classification criteria sets currently coexist
further add to the complexity observed in the diagnosis of these patients (Sharp, 1987;
Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 1996). Furthermore, the initial
description of MCTD as a benign autoimmune disease (Sharp et al., 1972) most likely
has jeopardized its relevance as independent identity. Nevertheless, involvement of vital
organs such as lung and heart in MCTD patients has long been reported by several
independent investigations (Badui et al., 1984; Smolen and Steiner, 1998; Venables,
2006; Watanabe et al., 2012; Gunnarsson et al., 2013), however; these findings have not
caught sufficient attention from the research community. Consequently, new efforts to
improve current classification methods for MCTD that could facilitate its early diagnosis
and potential treatment have been limited.
Despite the lack of support MCTD has had to be recognized as an independent
syndrome rather than an SLE like disease, there are a number of serological and clinical
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characteristics that support the independent nature of these autoimmune disorders. For
example, typically MCTD patients express elevated autoantibodies targeting U1 small
nuclear ribonucleoprotein (snRNP) specific proteins known as U1-70K, U1A and U1C
while those with SLE show anti-Smith (Sm) and anti-dsDNA antibodies (Luyckx et al.,
2005). Moreover, even though some SLE patients develop anti-U1 snRNP response; they
are able to retain IgM reactivity against these antigens while those with MCTD class
switch to IgG response instead (Vlachoyiannopoulos et al., 1996; Somarelli et al., 2011;
Mesa et al., 2013). Likewise, severe renal and central nervous system (CNS)
manifestations are observed in SLE patients (Zidan et al., 2013) while lung and heart
malfunctions are frequent in MCTD subjects (Watanabe et al., 2012; Gunnarsson et al.,
2013).
As a result of contrasting clinical characteristics and specific organ involvement
reported in SLE and MCTD patients, the recognition of MCTD remains useful in clinical
practices (Madisson, 2000; Venable 2006; Ortega-Hernandez et al., 2012). Currently
there is no available method capable of distinguish between these systemic autoimmune
syndromes given that the two classification criteria sets for SLE and four classification
rules for MCTD were designed to recognize either of these diseases but not to segregate
between them (Sharp, 1987; Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al.,
1996; Hochberg et al., 1997; Petri et al., 2012).The aim of this study is to develop novel
classification criteria specifically designed to segregate between SLE and MCTD
patients. To do this, 183 clinical and traditional laboratory test variables, 33 experimental
factors from cytokine and IgM response to antigens as well as six currently used
classification criteria sets were evaluated in the patient cohort (121 SLE and 41 MCTD).
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Analysis of the results revealed eight new classification rules for SLE and MCTD
distinction which are better classifiers than currently existent methods (p ≤ 0.0001).
Furthermore, these analyses corroborated that the combination of Malar rash and positive
results for double stranded DNA (dsDNA), FANA titers, elevated creatine proteinase
kinase (CPK) and IgM reactivity for SmD2amino-aids

14-21

(novel model 1) represents the

best classification criteria for SLE and MCTD patients with an overall accuracy of 80%
(p ≤ 0.0001). Additionally, we provide two panels of blood biomarkers that correlate with
specific organ involvement in either SLE or MCTD patients. Likewise, we highlight a
number of laboratory tests currently used to assist in the diagnosing of SLE or MCTD but
lacked classification power for any of these autoimmune syndromes. In summary, this
research described for the first time classification rules customized for the distinction of
SLE and MCTD. Despite required validation, these findings could assist in the early
diagnosis of patients with either SLE or MCTD which in turn may potentially allow the
development of a specific medical treatment to prevent damage of vital organs frequently
affected in these patient populations.

Patients and Methods
Selection of SLE and MCTD patients
In this study, a total of 165 patients previously diagnosed with either SLE (121
samples from 98 individuals) or MCTD (41 samples from 27 individuals) were obtained
following the Florida International University and University of Miami Institutional
Reviewed Board (IRB) accepted protocols (IRB numbers: 040308-00 as well as
20030724 and 20040286, respectively). Individuals were diagnosed with SLE by
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employing the American College of Rheumatology (ACR) criteria for lupus while
Alarcόn-Segovia criteria were utilized to diagnose those with MCTD (Amigues et al.,
1996; Hochberg et al., 1997). All the individuals included represent well characterized
patients that have been the subject of previous publications (Maldonado et al., 2006;
Perkins et al., 2008; Somarelli et al., 2011; Mesa et al., 2013).

Collection of clinical data
A total of 183 clinical variables were obtained from the 165 patients, when
available (Appendix 3). These variables include 74 clinical symptoms, 76 traditional
laboratory tests and 33 experimental blood markers. All the clinical variables were
recorded on the same date blood and/or urine samples were collected from the patient.
The traditional laboratory tests refer to standardized commercial laboratory assays
performed during the diagnosis of patients with SLE or MCTD. Experimental blood
markers variables include 18 cytokines and IgM reactivity for 15 different peptides
derived from U1 small nuclear ribonucleoprotein particle (snRNP). Detailed description
of each of the clinical manifestations as well as normal range and cut off values for
traditional and experimental laboratory tests are listed in Appendix 3.

Evaluation of classification criteria sets for SLE and MCTD patients
Two classification criteria sets available for diagnosing of SLE and four class
criteria set for MCTD identification were compared regarding their capability to
segregate patients with either autoimmune syndrome. The classification criteria sets for
SLE are known as ACR and the recently described Systemic Lupus International
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Collaborative Clinics (SLICC) (Hochberg et al., 1997; Petri et al., 2012) while those for
MCTD are named Alarcon-Segovia, Sharp, Kasukawa and Kahn (Sharp, 1987;
Kasukawa et al, 1988; Kahn et al., 1991; Amigues et al., 1996).

All clinical and

laboratory tests available from the 183 computerized medical records were employed to
assess the number of SLE and MCTD subjects from the patient cohorts that could fulfill
each of the six classification criteria sets. The accuracy, sensitivity and specificity of each
of the classification criteria sets were estimated using the standard clinical methods.

Construction of reduced classification criteria models for SLE and MCTD segregation
derived from established class criteria sets
The variables composing each of the two classification criteria sets for SLE and
four class criteria sets for MCTD diagnosis were employed in six independent forward
Binomial Logistic Regression (BLR) analyses using SPSS (version 18). These analyses
reveal which combinations of variables improve the segregation of SLE and MCTD when
compared to each of the individual variables included per classification criteria evaluated
(p ≤ 0.05). As result, six reduced models were obtained in which each of them correspond
to a smaller version of each of the six classification criteria considered in the analysis.
The accuracy, sensitivity and specificity for each of the reduced methods to classify SLE
and MCTD patients were calculated. Receiving Operating Characteristics (ROC) curves
were employed to rank the reduced models based in their power to segregate between
SLE and MCTD patients.
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Identifying reduced number of variables to develop new classification rule for SLE and
MCTD discrimination
Since this study includes 183 clinical variables but only 165 patients, an initial
selection of variables was required to maintain stability and robustness of any subsequent
statistical analysis performed. Knowing that the objective was to develop a new
classification rule customized for the discrimination of SLE and MCTD patients, all the
variables showing significant difference between patients with these autoimmune
disorders were selected (p ≤ 0.05). Likewise, all clinical and laboratory features included
in each of the reduced classification criteria models were also chosen given that forward
BLR demonstrate their improved power to discriminate between SLE and MCTD
patients (p ≤ 0.05). The variables selected to build a new classification rule include 21
clinical manifestations, 12 traditional laboratory tests and four experimental blood
markers (Appendix 4). Valvular heart disease, laboratory blood tests for calcium,
albumin/globulin and creatine kinase as well as the interleukin 17A (IL-17A)
experimental assay were initially selected but could not be included in the subsequent
statistical analysis given the reduced number of patients with available values for these
variables.

Developing novel classification criteria models for SLE and MCTD segregation
A total of 37 pre-selected variables which include clinical symptoms as well as
traditional and experimental laboratory tests (Appendix 4) were considered to develop
new classification models tailored to segregate between SLE and MCTD patients using
forward BLR analysis in SPSS (version 18). All 37 variables were considered to
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construct classification Model 1 while only clinical manifestations and standardized
laboratory tests (33 variables) were evaluated to build classification Model 2. The
probability of a patient to be classified as SLE or MCTD based on Model 1 or 2 are
defined by the following equations, respectively:

Model 1 = log

(

)

(

)

= -35 + 54(Malar rash) + 53(dsDNA) - 35(FANA titer)
– 55(CPK elevated) + 36 (IgM anti-SmD2 reactivity)

Model 2 = log

(
(

)
)

= 19 + 4(Malar rash) - 22(Synovitis) + 3(dsDNA) 24(Scl70) + 44(ANA)

where each of the models symbolize the log ratio of the combined variables in the SLE
group divided by that of the MCTD cluster (p ≤ 0.05). The probability of the sample to be
SLE or MCTD in each model is calculated by plotting the values of each of the
characteristics listed within parenthesis in each the independent equations. For each of
the models, a probability >0.5 indicates the patients belong to the SLE group while a
probability <0.5 classify the patient as MCTD.
Statistical analysis
Significant differences between SLE and MCTD patients for each of the 187
clinical variables included in this study were determined by Chi (X) square or
independent sample T test in SPSS (version 18) when the value was nominal or
numerical, respectively (p ≤ 0.05). Correlations between laboratory tests and clinical
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manifestations observed in either SLE or MCTD patients were determined by Ttest/ANOVA with repeated measurements within patients for test with numerical values
while a generalized linear mixed model was applied to assays with binary values (p ≤
0.05). The resulting p-values for each of the correlations were used to construct a
heatmap for each autoimmune syndrome in R where significant correlations before and
after Bonferroni correction as well as variables with no correlation are color coded in
white, blue and red, respectively. Alopecia, swelling of neck lymph nodes, rheumatoid
nodule, hemolytic anemia, avascular necrosis, pulmonary vascular lesions, renal clot,
renal arterial stenosis, chorea and phychosis were not included during the correlation
analysis because insufficient sample size and/or lack of sufficient variability in SLE
and/or MCTD cohorts.

Receiving Operating Characteristic (ROC) curves were

performed in SPSS (version 18) to corroborate and compare classification power of each
of the models resulting from forward BLR (p ≤ 0.05).

Results
Contrasting clinical and serological features are exhibited by SLE and MCTD patients
Each of the 183 clinical variables included in this research (Appendix 3) were
evaluated to assess significant differences between SLE and MCTD populations. We
identified 35 variables that significantly differ between these autoimmune diseases
including clinical symptoms related to skin, muscle , kidney and heart tissues as well as
a 18 serological assays (p ≤ 0.05) (Figure 8). Interestingly, the skin derived variables
(Raynaud’s Malar and Discoid rashes) tend to be higher in SLE than MCTD patients (p ≤
0.05). Likewise, the study of muscle features showed that SLE patients appear to have
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greater inflammation of the joints and extremities while MCTD individuals exhibit
prevalence of myositis and muscle weakness (p ≤ 0.05). As expected, renal disease and
renal hematuria are elevated in SLE but not MCTD patients (p ≤ 0.05). Additionally,
myocardial infarction is elevated in MCTD patients while valvular heart disease seems to
be more frequent in SLE individuals (p ≤ 0.05). Evaluation of the serological assays
revealed that with the exception of creatine phosphate kinase and positive antibodies for
topoisomerase (Scl-70 +), all the traditional laboratory tests were higher in the SLE
population when compared to the MCTD group (p ≤ 0.05). Similarly, all the experimental
tests which include identification of interleukin 17A and IgM reactivity for U1A, SmD1
and SmD2 are elevated only in SLE but not MCTD individuals (p ≤ 0.05). Consequently,
this analysis showed that SLE and MCTD patients exhibit unique clinical manifestations
and molecular markers (p ≤ 0.05).

Molecular markers associations with unique tissue damage are specific to either SLE or
MCTD patients
Each of the laboratory tests analyzed in this study was individually correlated with
clinical symptoms presented in patients diagnosed with SLE or MCTD (Figures 2 and 3).
The resulting p-value heatmap uncovered the SLE cohort seven clinical manifestations
significantly associated with IL33 (oral ulcers, leukopenia and lymphopenia), IL12p40
(telangiectasia and joints deformity), BAFF (Thrombosis) and positive protein in urine
(renal disease) (p ≤ 0.05) (Table 5 and Figure 9). Different significant correlations were
detected in the MCTD population where seven molecular markers were significantly
associated with nasal ulcers (BAFF), oral ulcers (IL33), anemia (C3 and C4 level as well
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as IgM and IgG rheumatoid factor ELISA titer) and pleuritis (IL17A) (p ≤ 0.05) (Table 5
and Figure 10). It is noteworthy that IL33 correlates with oral ulcers equally in SLE and
MCTD (p ≤ 0.05). Interestingly, 44% (4/9) of the biomarkers that show significant
correlations with specific clinical symptoms correspond to new experimental blood
antigens that showed reactivity in SLE and/or MCTD patients. In this way, the p-value
heatmaps resulting from correlation analysis suggest that correlations of molecular
markers and clinical manifestations are unique to either SLE or MCTD patients (p ≤
0.05).

Classification criteria sets are not designed for segregating SLE and MCTD patients
Each of the six criteria sets for the classification of either SLE or MCTD was
applied to the patient cohorts to evaluate their capacity to segregate between these
autoimmune syndromes (Table 6). These analyses revealed that there is virtually no
difference in the accuracy of the new (Systemic Lupus International Collaborating
Clinics (SLICC)) and old (ACR) SLE classification criteria sets (p ≤ 0.05) (Table 6). This
is an important observation considering SLICC is composed by 25 additional variables
that are not listed in the ACR class criteria (Hochberg et al., 1997; Petri et al., 2012).
Specifically, SLICC and ACR showed elevated sensitivity (93.26% and 85.39%,
respectively) but both have deficient specificity (13.33, and 24.44%, respectively) (Table
6). When evaluating all the MCTD class criteria sets, the Alarcόn-Segovia showed the
best accuracy (72.39%) at discriminating between SLE and MCTD even though Sharp,
Kasukawa and Kahn class criteria sets also exhibited significant segregation between the
two autoimmune disorders (p ≤ 0.05) (Table 6). In contrast to SLICC and ACR
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classification criteria, the Alarcόn-Segovia exhibits moderate sensitivity (64.44%) and
specificity (76.40%) in distinguishing between MCTD and SLE patients (p ≤ 0.05) (Table
6). Taken all these together, the data showed that the six established methods for the
classification of SLE (ACR and SLICC) and MCTD (Alarcόn-Segovia, Sharp, Kasukawa
and Kahn) lack power to segregate patients diagnosed with either these syndromes.

Regression analysis of existent classification criteria sets uncover essential factors
required for SLE and MCTD segregation
Six independent forward BLR analyses with variables corresponding to those listed in
each of the six classification criteria were performed to construct six reduced models.
Evaluation of the reduced models exposed 6 combinations from 18 essential features with
significant power to differentiate between SLE and MCTD patients (Table 7).
Comparison of all six reduced models reveals that the reduced Kasukawa (rKasukawa)
shows the highest accuracy (85.5%) at segregating between these autoimmune syndromes
which power is derived by the combination of Raynaud’s phenomenon, Malar rash,
adenopathies, sclerodactyly and muscle weakness (p ≤ 0.05) (Table 7). Specifically, the
rKasukawa not only showed superior sensitivity (75%) and specificity (90.5%) when
compared to the other five reduced models but seems a better classifier than the AlarcόnSegovia classification criteria to discriminate between SLE and MCTD patients (Table
7). Indeed, all the reduced models are better classifiers for SLE and MCTD patients when
compared to their corresponding complete class criteria (Tables 2 and 3). Consequently,
the forward BLR revealed four groups composed by combination of 18 core variables
with the capacity to segregate between SLE and MCTD (p ≤ 0.05).
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ROC curves confirmed the classification power of reduced class criteria models
A total of six individual ROC curves analyses were performed to confirm the
segregation power of the variable per criteria set when compared to the corresponding
complete classification criteria (Table 6) as well as proposed reduced models (Table 7).
As expected, the ROC analysis confirmed that all reduced models are a better classifier
for these autoimmune syndromes than any of the complete class criteria or any variable
included in them (p ≤ 0.0001) (Figure 11). Likewise, the analysis revealed that two
laboratory tests previously identified by BLR (positive dsDNA and RNP in Table 7) have
individual power to distinguish between SLE and MCTD patients (p ≤ 0.05) (Figure 11).
Also, eight of the clinical symptoms predicted by BLR (synovitis, Malar rash, nonerosive arthritis, acrosclerosis, Raynaud’s, esophageal hypomotility, sclerodactitily and
muscle weakness in Table 7) showed to have individual power to segregate between SLE
and MCTD (p ≤ 0.05) (Figure 11). In addition, the ROC analysis uncovered that swollen
hands and negative laboratory results for Sm (Sm-) each have independent capability to
separate SLE from MCTD patients (p ≤ 0.05) (Figure 11). Therefore, the ROC analysis
exposed ability of swollen hands and Sm- results in segregating between these
autoimmune disorders as well as confirmed the power of 10 out of the 18 variables
identified by BLR in differentiating between SLE and MCTD patients (p ≤ 0.05).

Construction of novel class criteria sets to assist diagnosing of SLE and MCTD
A total of 37 pre-selected variables (Appendix 4) were employed in forward BLR
analysis to develop new predicted models tailored specifically for SLE and MCTD
classification. When considering experimental and traditional laboratory assays as well as
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clinical symptoms, the analysis revealed that the combination of Malar rash, positive
results for dsDNA and FANA titers, elevated creatine phosphate kinase (CPK) and IgM
anti-SmD2amino-acids 14-21 reactivity (referred to as Model 1) exhibits an overall accuracy of
80% in discriminating between SLE and MCTD patients with sensitivity and specificity
of 92% and 74%, respectively (p ≤ 0.0001) (Table 8). A separate forward BLR analysis
was performed utilizing only traditional laboratory tests and clinical manifestations from
patients with either SLE or MCTD. The data confirmed that the combination of Malar
rash, synovitis as positive results for dsDNA, topoisomerase (Scl70) and anti-nuclear
assay (ANA) (named Model 2) showed a 74% accuracy at discerning between these two
autoimmune syndromes with 83% sensitivity and 69% specificity (p ≤ 0.0001) (Table 8).
In summary, the BLR analysis uncovered two novel class criteria sets (Models 1 and 2)
which were custom built for discriminating between SLE and MCTD patients (p ≤
0.0001).

Model 1 represents the best classification rule to discern between SLE and MCTD
patients
Novel proposed classification Models 1 and 2 (Table 8) were included in ROC
curves analysis along with each of the classification criteria for SLE and MCTD (Table
6) and their corresponding reduced models (Table 7) to compare their classification
power for SLE and MCTD patients. The analysis confirmed that Model 1 exhibits the
highest capacity to discern between SLE and MCTD with AUC = 0.930 (p ≤ 0.0001)
(Figure 12). Likewise, rKasukawa model, rACR model, rSharp model, Model 2, rSLICC
model, rAlarcon-Segovia model and Sharp classification criteria occupy the second to
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eight place in having power to classify SLE and MCTD patients (p ≤ 0.05) (Figure 12).
The rKahn model and the rest of the classification criteria sets (Kasukawa, AlarconSegovia, Kahn, ACR and SLICC) were unable to segregate patients diagnosed with any
of these autoimmune syndromes (Figure 12). Therefore, ROC curves analysis confirmed
that the combination of variables included in Model 1 are the best classification rule for
SLE and MCTD patients when compared to Model 2, all six classification criteria sets
available for these autoimmune disorders as well as their corresponding reduced models
(p ≤ 0.0001).

Discussion
Since its initial description by Sharp et al. (1972), the recognition of MCTD as an
unique disease has been constantly challenged, mainly due to the number of overlapping
characteristics shared by patients diagnosed with SLE (Aringer et al., 2005; NowickaSauer et al., 2012). Currently, in cases where the concept of MCTD is acknowledged, it is
often portrayed as a subset of SLE patients with good prognosis despite exhibiting
features listed in SLE and MCTD classification criteria sets and prevalence of lung and
heart problems (Badui et al., 1984; Smolen and Steiner, 1998; Venables, 2006; Watanabe
et al., 2012; Gunnarsson et al., 2013; Bertsias et al., 2013). The reported contrasting
organs involvement in patients with diagnosis of MCTD (lung and heart) when compared
to those with SLE (kidney and CNS) provides evidence of the clinical relevance of the
MCTD concept to prevent and/or treat organ malfunction in these autoimmune
syndromes, regardless if MCTD is recognized as a separate illness or a SLE subtype.
Given that available classification criteria sets were developed to identify either SLE or
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MCTD subjects but not to segregate between them, it seems imperative to design
classification rules specifically tailored to discriminate SLE and MCTD patients since
early class group identification could influence the type of medical plan developed to
impede or reduce organ damage, thus potentially improving the patient’s prognosis. This
investigation provides, for the first time, eight different classification rules strategically
derived for the segregation of SLE and MCTD patients. Analysis of the resulting data
confirmed that all eight proposed models exhibit a higher power to correctly identify SLE
or MCTD patients than any other available class criteria set (p ≤ 0.0001). Despite a
required validation step, the proposed models highlight clinical and molecular features
with power to segregate SLE and MCTD subjects while providing additional evidence to
support the independent etiology of these autoimmune syndromes.
In congruency with previous reports (Vlachoyiannopoulos et al., 1996; Luyckx et
al., 2005; Somarelli et al., 2011; Watanabe et al., 2012; Gunnarsson et al., 2013; Mesa et
al., 2013; Zidan et al., 2013), the analysis of 187 medical records documented for SLE
and MCTD patients revealed that 35 clinical manifestations and molecular features are
significantly different in the two disease states (Figure 8). The prevalence of skin rashes
in SLE while myositis and muscle weakness was presented in MCTD was expected since
these are typical clinical manifestation associated with each of these autoimmune
illnesses (Uthman et al., 1996; Belibou et al., 2012; Szodoray et al., 2012). Like others
(Watanabe et al., 2012; Gunnarsson et al., 2013; Zidan et al., 2013), the data showed that
specific organ malfunction was involved with each of these syndromes where renal
disease was elevated in SLE cohort while myocardial infarction was more frequently in
the MCTD population (p ≤ 0.002). Additionally, the correlation analyses support the idea
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that SLE and MCTD are indeed separate disorders given that unique correlations of
molecular markers and clinical symptoms are observed in either SLE or MCTD cohorts
(Figures 2 and 3). An interesting association revealed was between IL17A and pleuritis
observed only in MCTD but not SLE subjects (Table 5). In addition to representing a
novel potential blood biomarker, the association of IL17A and pleuritis might indicate
pleural inflammation related to bacterial infections as has been recently reported
(Monguilhott Dalmarco et al., 2011; Kollintza et al., 2013). It is noteworthy to mention
that the frequency of lung disease in the SLE and MCTD cohorts does not differ (44%
and 48% respectively). Given that some studies have reported the predominance of lung
disease in MCTD patients (Sasaki et al., 2011; Gunnarsson et al., 2012) while others have
uncovered that lung malfunction in these patients is lower than expected (Gunnarsson et
al., 2013), these results suggest that additional investigations encompassing bigger
MCTD samples and inclusion of other autoimmune syndromes are required to assess if
lung disease should be considered as a target organ during the diagnosis and treatment of
MCTD. Consequently, the data provide grounds to suggest that new classification rules
customized for SLE and MCTD segregation should be developed to prevent and/or
reduce organ involvements in these patients.
The evaluation of ACR, SLICC, Alarcόn-Segovia, Sharp, Kasukawa, and Kahn
criteria sets revealed the average capability of segregating SLE and MCTD patients
(Table 6). Specifically, the misclassification rate of patients using any of these methods
ranges from 36% to 87% for MCTD subjects (16/45 and 39/45 MCTD incorrectly
grouped by Alarcόn-Segovia and SLICC, respectively) while varies from 7% to 56% for
SLE (6/89 and 48/85 SLE mistakenly clustered by SLICC and Kasukawa, respectively).
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This deficiency of classification power was expected given that the inclusion of MCTD
patients was not recognized during the development of SLE classification criteria sets
(Tan et al., 1982; Hochberg et al., 1997; Petri et al., 2012). By contrast, patients
diagnosed with SLE and other autoimmune syndromes were included during the
production of each of the four classification criteria sets for MCTD (Amigues et al.,
1996). Nevertheless, these studies did not included well characterized MCTD cases and
rather choose the presence of positive anti-U1 snRNP antibodies as patient inclusion
criteria despite knowing these antigens elicit a response in SLE and MCTD subjects
(Amigues et al., 1996; Sato et al., 2010; Nagai et al., 2012, Mesa et al., 2013).
Consequently, these findings provide evidence to suggest that currently available SLE
and MCTD classification criteria sets do not exhibit sufficient power to correctly identify
SLE or MCTD patients (Table 6) (Figure 11).
The regression analysis identified eight different novel classification rules (Tables
3 and 4) which exhibit significantly higher capability to segregate SLE and MCTD
patients than any other classification criteria sets available (p ≤ 0.05) (Figure 12).
Particularly, Model 1 composed by the presence of Malar rash, elevated CPK and
positive results for dsDNA, FANA and IgM anti-SmD (Table 8), represents the best
classifier to identify SLE and MCTD patients with an significant AUC of 0.930 (p ≤
0.0001) (Figure 12). The segregation power of the combination of variables in Model 1
was predicted given that, with the exception of elevated CPK; all the other clinical
characteristics and lab tests have been repetitively reported elevated in SLE patients but
reduced in MCTD subjects (Vlachoyiannopoulos et al., 1996; Luyckx et al., 2005;
Somarelli et al., 2011; Mesa et al., 2013). The misclassification rate of proposed Model 1
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attains 8% for MCTD patients (2/24 incorrectly clustered) and 26% for SLE subjects
(11/42 falsely grouped). In this way, the overall classification power for SLE and MCTD
shown by Model 1 is significantly improved when contrasted with existent validated
classification criteria sets (p ≤ 0.0001) (Figure 12). Additionally, the results revealed that
rKasukawa, rACR, rSharp, Model 2, rSLICC and rAlarcόn-Segovia follow Model 1 in
their power to segregate between SLE and MCTD patients (p ≤ 0.05) (Figure 12). The
ROC curves confirmed that Sharp classification criteria exhibit significant ability to
discern between these autoimmune syndromes however the average AUC (0.684)
highlights the average power of this criteria set (p ≤ 0.05) (Figure 12).
Taking all of this together, this study shows evidence to support the relevance of
recognizing the MCTD concept while providing, for the first time, eight different
classification rules tailored for the specific classification of SLE and MCTD patients.
Given that these results and others have identified specific organ involvement in either
SLE or MCTD patients (Figure 8) (Vlachoyiannopoulos et al., 1996; Luyckx et al., 2005;
Watanabe et al., 2012; Gunnarsson et al., 2013; Mesa et al., 2013; Zidan et al., 2013), it
highlights the clinical value of MCTD diagnosis given that the type of medical regime
delivered to a patient will rely on the potential development of specific organ(s)
malfunction. Aware of the lack of methods designed to segregate between these
autoimmune disorders (Table 6 and Figure 11), we described eight different novel
classification rules (Tables 3 and 4) from which Model 1 (derived by the combination of
Malar rash, elevated CPK and positive results for dsDNA, FANA and IgM anti-SmD)
represents the best classifier from those evaluated with a power of 93% to distinguish
between SLE and MCTD patients (Figure 12). Noteworthy the limitations and the need
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for a validation step of the current findings, we believe that the time has come to
recognize the clinical relevance of the MCTD concept to prevent and/or treat organ
malfunction. Consequently, the proposed classification rules presented in this research
pioneers the efforts to attain the development of new consensus criteria custom made for
segregating between SLE and MCTD patients.
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Table 5: List of molecular markers associated with clinical manifestations in SLE
and MCTD patients

Tissue
affected

Molecular
markers

Skin

BAFF
IL33

Joints

IL12p40

Blood

C3 level
C4 level
IgM RF ELISA titer
IgG RF ELISA titer
IL33

Heart
Kidney

BAFF
IL17A
Urine protein +

SLE

MCTD

ø
Oral ulcers
Telangiectasia
Deformity
ø
ø
ø
ø
Leukopenia
Lymphonia
Thrombosis
Renal disease

Nasal ulcers
Oral ulcers
ø
ø
Anemia
ø
ø
ø
Pleuritis
ø

Experimental molecular markers are in italics while traditional lab tests are not. All the markers listed
are associated with each of the clinical symptoms with a p-value ≤ 0.05 and Bonferroni correction. The
empty symbol (ø) represents no significant correlation determined with p ≤ 0.05 after Bonferrori
correction. Interlukins are denoted as follow: IL33, IL12p40, BAFF and IL17A). “RF” stands for
rheumatoid factor while urine protein + corresponds to protein detection in urine samples.
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Table 6: Evaluating SLE and MCTD classification criteria sets in patient cohort
included in the present study

Classification
criteria sets
S
L
E

M
C
T
D

SLE

MCTD
p-value

Correctly
classified

Incorrectly
classified

Correctly
classified

Incorrectly
classified

SLICC

83

6

6

39

0.207

ACR

76

13

11

34

0.161

Alarcόn-Segovia

68

21

29

16

<0.0001

Sharp

48

41

37

8

<0.0001

Kasukawa

37

48

42

3

<0.0001

Kahn

82

7

11

34

0.008

SLICC and ACR stands for Systemic Lupus International Collaborating Clinics and American College of Rheumatology,
respectively. The analysis were performed in SPSS (version 18) and included 89 SLE patients and 45 MCTD individuals.
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Table 7: Description of reduced models for each SLE and MCTD classification
criteria

Reduced models for
each classification
criteria
S
L
E

M
C
T
D

Accuracy

p-value

Features included in the
reduced models

rSLICC

79.6%

<0.0001

Discoid rash, joint synovitis, leukopenia,
ANA+, dsDNA+, Sm+ and phospholipid +

rACR

74.4%

<0.0001

dsDNA+, hemolytic anemia, Malar rash
and Non-erosive arthritis

rAlarcόn-Segovia

74.2%

<0.0001

Synovitis and acrosclerosis

rSharp

78.4%

<0.0001

Severe myositis, Raynaud’s or esophageal
hypomotility, RNP+, Sm+

rKasukawa

85.5%

<0.0001

Raynaud’s, adenopathies, Malar rash,
sclerodactyly and muscle weakness

rKahn

69.7%

<0.0001

Raynaud’s and synovitis

SLICC and ACR stands for Systemic Lupus International Collaborating Clinics and American College of Rheumatology,
respectively. Anti Nuclear Antibody positive (ANA+) as well as positive antibody detection of double stranded DNA (dsDNA+),
Smith protein (Sm+) phospholipid (phospholipid +) and Ribo-Nucleo-protein (RNP+) are indicated. The analysis were performed
using the binomial logistic regression (BLR) function in SPSS (version 18) and included 89 SLE patients and 45 MCTD
individuals.

87

Table 8: Description of novel models for segregation of SLE and MCTD patients

Proposed
models

Features included
in each model

Cut-off

Accuracy

p-value

Model 1

Malar rash, dsDNA+, FANA titers,
elevated CPK and IgM reactivity for
SmD2amino-acids 14-21.

0.42

80.30%

<0.0001

Model 2

Malar rash, synovitis, dsDNA+,
Scl70+, ANA+

0.28

73.64%

<0.0001

The models were obtained using binomial logistic regression (BLR) function in SPSS (version 18) when clinical
variables as well as traditional and experimental laboratory tests from SLE and MCTD patients were considered
(Appendix 4). Model 1 was built using experimental and traditional variables from 42 SLE and 24 MCTD patients
while only traditional variables derived from 75 SLE and 35 MCTD patients were considered for Model 2. Values under
the cut off points will be classified as SLE while those above it will be identified as MCTD. Positive antibody detection
of double stranded DNA (dsDNA+), toposiomerase (Scl70+) and Anti Nuclear Antibody positive (ANA+) are indicated.
The experimental variable is denoted in italics.
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Figure legends
Figure 8: SLE and MCTD differ in the prevalence of clinical characteristics and
molecular factors. In each graph, the inner circle represents the MCTD cohort while the
outside circle consists of the SLE population. Positive and negative values for each of the
variables are represented by green and red, respectively. History of proximal muscle
weakness, observed proximal muscle weakness, observed joints swelling, symmetric
joints swelling, low extremity swelling are denoted by “H prox muscle weakness”, “O
prox muscle weakness”, “O joints swelling”, “S joints swelling” and “L extremity
swelling”, respectively. Positive laboratory tests for ribonucleoprotein (RNP), Smith
proteins (Sm), double stranded DNA (dsDNA), Fluorescent Antinuclear Antibodies
(FANA), anti-La antibodies (SSP) and topoisomerase (Scl) are indicated with “+”.
Experimental antigens as opposed to traditional laboratory tests are in italics.

Figure 9: Proposed biomarker panel for clinical manifestations observed in SLE
patients. In the plot, the clinical symptoms and laboratory tests are on the “x” and “y”
axis, respectively. The white, blue and red boxes indicate significant correlations,
significant correlations after Bonferroni corrections and no correlations, respectively (p ≤
0.05). Hand swelling, proximal scleroderma, any heart clot, valvular heart diseases,
pulmonary hypertension, pulmonary fibrosis, gastric reflux, lymph nodes swelling,
morning stiffness, myocard infarction and interlukin receptor BAFFR were initially
considered in the analysis but not included due to the reduced sample size for each of
these variables.
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Figure 10: Specific blood markers correlate with clinical symptoms in MCTD
patients. Laboratory tests performed in MCTD subjects are displayed in the “y” axis
while clinical manifestations exhibit in this patient population are on the “x” axis. The
white, blue and red boxes indicate significant correlations, significant correlations after
Bonferroni corrections and no correlations, respectively (p ≤ 0.05). Renal proteinuria,
hematuria and cell cast, stroke, venous heart clot, lung disease, synovitis, symmetric
swelling of the joints, observed proximal muscle weakness and calcinosis were initially
considered for the correlations but not included in the final analyses given the reduced
sample size available in the MCTD cohort for these variables.

Figure 11: Reduced models for each SLE and MCTD classification criteria exhibit
better power in discriminating between SLE and MCTD patients. Each of the
reduced models were obtained by applying binomial logistic regression (BLR) in SPSS
(version 18) when all the variables per classification criteria were considered in SLE (n =
89) and MCTD (n = 45) patients. The Systemic Lupus International Collaborating Clinics
(SLICC) and American College of Rheumatology (ACR) classification criteria sets for
SLE diagnosis are denoted with A and B, respectively. The Alarcόn-Segovia (C), Sharp
(D), Kasukawa (E) and Kahn (F) represent the classification criteria sets for diagnosing
MCTD patients. In each plot, the area under the curve (AUC) from Receiving Operating
Characteristics (ROC) curves are on the y axis. Each of the columns represent
characteristics and the reduced model included per classification criteria. The lines on top
of each column are standard error. Significant difference between SLE and MCTD
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patients with p-values ≤ 0.05, ≤ 0.005 and ≤ 0.0001 are denoted with “*”, “**” and
“***”, respectively.

Figure 12: Proposed Model 1 exhibits the highest discrimination power in
identifying SLE and MCTD patients. The x axis includes the classification criteria for
SLE and MCTD, their correspondent reduced models as well as the new proposed models
(Model 1 and Model 2) for segregation of patients with these autoimmune syndromes.
The y axis represents the area under the curve (AUC) resulting from the Receiving
Operating Characteristics (ROC) curves analysis. Variables with significant power to
differentiate between SLE and MCTD with p-values of 0.05, 0.005 and ≤ 0.0001 are
indicated with “*”, “**” and “***”, respectively.

91

Figure 8: SLE and MCTD differ in the prevalence of clinical characteristics and
molecular factors
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V. CONCLUSIONS
The recognition of MCTD as a separate disorder from SLE has remained
debatable since its initial description in 1972 (Sharp et al., 1972; Aringer et al., 2005;
Nowicka-Sauer et al., 2012). Nevertheless, the clinical relevance of the MCTD concept to
identify individuals with different organ malfunction from patients that fulfill the SLE
classification criteria has been documented (Badui et al., 1984; Smolen and Steiner,
1998; Venables, 2006; Watanabe et al., 2012; Gunnarsson et al., 2013; Bertsias et al.,
2013). This investigation provides clinical and molecular evidence to support the
independent etiology of SLE and MCTD. The experimental approach suggests that
models resulting from the IgM anti-U1 snRNP titers could be considered as a potential
blood biomarkers capable of differentiating SLE from MCTD patients as well as
molecular indicators for lung and kidney disease in patients suffering from any of these
disorders (p ≤ 0.005). Likewise, derivation of the data analysis resulted in the description
of novel classification rules for SLE and MCTD with significant improved classification
power when compared to available methods (p ≤ 0.005). Even knowing that these
findings must be validated and recognizing the limitations of the approached utilized in
this research, the results strongly suggest that the described biomarkers and classification
criteria sets might have clinical relevance during the accurate identification of MCTD
therefore potentially improving patients’ prognosis.
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APPENDIX 1
Protocol for generating a 3D protein structure and applying a heat scale to residues
of interest
This protocol assumes that the amino acid sequence of a protein of interest is available.

Generating a heat map scale
The goal for generating a heat map scale is to pick one group as a baseline and then
compare how far above or below that baseline some other group performs. The resulting
deviation should range from 0 to 1. In general, one picks the control group (i.e. healthy
subjects) as the baseline. For a four color heat scale of blue to green to yellow to red, with
blue being least intense and red being most intense, the following procedure can be used.
1. For each value measured, calculate deviation by the test group from the control
group using the formula:
Deviation=0.5+ Test-Control
2.

Calculate the appropriate RGB values for the deviation.

a.

In Excel, place the value for Deviation in cell B2.

b.

To calculate the Red RGB value, place the following code in cell C2:
•

c.

=IF(B2>0.67,255,IF(B2>0.33,255*(3*B2-FLOOR(3*B2,1)),0))

To calculate the Green RGB value, place the following code in cell D2:
•

=IF(B2>0.67,-255*(3*B2FLOOR(3*B2,1))+255,IF(B2>0.33,255,255*(3*B2FLOOR(3*B2,1))))
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d.

To calculate the Blue RGB value, place the following code in cell E2:
•

3.

=IF(B2>0.33,0,-255*(B2*3-FLOOR(B2*3,1))+255)

Use the resulting RGB values as custom colors in some other application. An

example is Case 1 step 5 below.

Generating 3D structures
In terms of an experimentally determined 3D structure of the protein, there are three
cases that are addressed: (1) no such 3D structure is available; (2) a partial structure is
available; or (3) a complete structure is available.

Case 1
1. Submit the amino acid sequence to the I-TASSER protein structure prediction
server to generate 3D structures of your protein. The server is located at:
http://zhanglab.ccmb.med.umich.edu/I-TASSER/.
2. Download and install PyMOL to visualize the predicted structures. It can be
obtained at: http://www.pymol.org/.
3. Open the I-TASSER model of interest (usually the one with the highest C-score)
in PyMOL.
4. Define your residues of interest using the select command.
•

Example, to define residues 10 through 20 by the name p1, at the
PyMOL> prompt type:

•

select p1, resi 10–20

Define your custom colors from the heat map scale using the set_color command.
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•

Example, to define a custom color with RGB values of R=127, G=255,
B=212, type:

•

set_color p1_color = [127, 255, 212]

Assign your custom colors to your residues of interest.
•

For the example residues and color above, type:

•

color p1_color, p1

Repeat steps 4 through 6 for each set of residues of interest.
Choose how you would like your structure represented. From the PyMOL viewer
next to “all”, click S for Show, then “as” and choose either lines, sticks, ribbon, or
cartoon.
To change the background color to white, type:
•

bg_color white

Orient the structure as desired, or click the Orient button in the PyMOL console.
If planning to create an animation, be sure to leave sufficient white space around the
structure.
To save a high quality image of the structure, type:
•

ray

•

Click on File->Save Image As->PNG… and select your filename

For a rotated image, type:
•

rotate y, 180

•

Repeat step 11

Open your image in a graphics package (for example, Photoshop) to add labels.

112

To create an animated GIF of your structure, first install ImageMagick. It can be
obtained at: http://www.imagemagick.org/script/index.php.
Create a series of still images to serve as frames for your animation. From the
PyMOL prompt, type:
•

mset 1 x60

•

util.mrock 1,60,180

•

set ray_trace_frames=1

•

mpng frame

Copy your frames to a temporary folder and open a command prompt. Type:
•

convert -delay 1 -loop 0 frame*.png animated.gif

Case 2
1. Follow steps 1 and 2 as in Case 1.
2. Compare your predicted structures to your experimentally determined structure in
PyMOL by superposition.
a.

Open your experimentally determined structure and your I-TASSER models in

PyMOL.
b.

For each comparison, where model is the name of your predicted structure and

experimental is the name of your experimentally determined structure, type:
c.

super model, experimental

d.

Find the best ratio of retained atoms to RMS value from the final line of output.
Using only the best superposition, follow steps 4 through 15 as in Case 1.
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Case 3
1. Follow steps 2 and steps 4 through 15 as in Case 1.
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APPENDIX 2

Variables
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
P13
P14
P15

IgM reactivity

IgG reactivity

AUC

SE

p value

AUC

SE

p value

.562
.570
.567
.522
.575
.579
.558
.598
.508
.547
.509
.517
.560
.613
.532

.055
.057
.061
.059
.058
.058
.059
.060
.060
.059
.058
.056
.056
.053
.060

.286
.227
.251
.710
.197
.173
.321
.091
.890
.424
.874
.773
.305
.052
.583

.863
.613
.796
.925
.933
.842
.787
.857
.653
.867
.817
.850
.804
.895
.849

.036
.050
.043
.024
.029
.037
.044
.039
.047
.035
.041
.040
.046
.033
.043

<.0001
.053
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
.008
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
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APPENDIX 2, continuation

Variables
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11
P12
P13
P14
P15

IgM reactivity
AUC
.631
.547
.551
.537
.570
.581
.561
.548
.577
.585
.574
.584
.610
.600
.605

SE
.053
.053
.054
.054
.053
.053
.054
.054
.053
.052
.052
.052
.051
.052
.053

p value
.018
.402
.358
.500
.210
.147
.269
.387
.164
.124
.185
.128
.048
.072
.060
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IgG reactivity
AUC
.587
.534
.536
.505
.549
.510
.516
.527
.538
.528
.502
.536
.569
.556
.545

SE
.054
.056
.054
.056
.054
.055
.054
.057
.053
.056
.056
.056
.055
.055
.056

p value
.119
.540
.517
.922
.374
.852
.780
.624
.498
.745
.978
.512
.214
.316
.422

APPENDIX 2, continuation

Variables
IgM P1 OD
IgM P13 OD
IgM P4 OD + IgM P10 OD
FANA titters
RNP positive
Sm positive
SSA positive
SSB positive
SCL positive
DNA elevated
ds DNA titters
IgM P4/P10 OD + DNA elevated
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AUC
.664
.618
.731
.553
.589
.638
.554
.561
.565
.665
.605
.798

SE
.061
.063
.057
.066
.063
.065
.068
.066
.070
.065
.062
.052

p value
.016
.084
.001
.437
.189
.043
.428
.374
.338
.023
.123
<.0001

APPENDIX 3

Variable

Definition

Telangiectasia

Skin telengectasia observed

Nasal ulcers

Skin nasal ulcers observed

Oral ulcers

Skin oral ulcers observed
Raynaud: a pattern of color changes in the fingers as
follows: pale/white followed by blue then red when the
hands are warmed; color changes are usually preceded
by exposure to cold or emotional upset

Raynaud

Skin hand swelling history

Hand swelling by history

Skin hand swelling observed

Hand swelling observed
Skin sclerodacytyl / acrosclerosis

Skin

Sclerodactyly

Skin digital pitting

Pitting

Skin alopecia-patchy or generalized

Alopecia
Malar rash

Skin malar rash- fixed erythema, flat or raised, over the
malar eminences, tending to spare the solabial folds

Discoid rash

Skin discoid rash- erythematous raised patches with
adherent keratotic scaling and follicular plugging.
Atrophic scaring seen in older lesions
Skin rash other by history or exam

Skin rash

Skin photosensitivity- skin rash as a resulf of unusual
reaction to sunlight by history or exam

Photosensitivity

Skin calcinosis observed

Calcinosis

Skin proximal scleroderma / extend at or above wrist

Proximal scleroderma

Skin sicca- xerophthalmia and xerostomia

Sicca
Myositis

Myositis

Myalgia

Myalgia-subjective muscle acking involving proximal
muscles
Arthralgia

Muscle

Arthralgia

Any objective weakness in the proximal muscles

Observed proximal weakness

A subjective history of any proximal muscle weakness

History proximal weakness
Muscular HAND SWELLING SPECIFIC

At least one area swollen in a wrist, mcp, or pip joint

Muscular HAND SWELLING GENERAL

Muscular hand swelling

Muscular HAND SWELLING HISTORY

Swelling of the hand by history

Muscular HAND SWELLING OBSERVED

Swelling of the hands observed
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Morning stifness lasting at least 1 hour before maximal
improvement

Morning stiff

Joint tenderness observed

Join tender

Synovitys

Joints

Synovitys
Join swellling history

History of joint swelling

Join swellling obs

Joint swelling observed

Swelling joints > 3

Swelling of 3 or more joints (pip, mcp, wrist, elbow,
knee, ankle and mtp)

Symmetric swelling

Symetric swelling observed
Joints pain

Joints pain

Joints deformity

Joints deformity

Any lymphadenopathy

Lymph nodes

Any lymphadenopathy

Gastro

Lympnodes swelling

Lympnodes swelling
Neck lympnode Swelling

Neck lympnode swellin

Axila lympnode Swelling

Axila lympnode swellin

Groin lympnode Swelling

Groin lympnode swellin

Rheum nodule

Observed rheumatoid nodule- subcutaneous nodules
over bony prominences or extensor surfaces, or in
juxtaarticular regions

Gastric reflux

Gastric reflux as diagnosed by patient symptoms of
heartburn, acid reflux or chest pain and radiographic
studies and/or endoscopy
Anemia

Anemia

Hemolytic anemia

Blood

Anemia hemolyti

Leukopenia

Leukopenia
Lymphopenia

Lymphopenia, total lymphocyte count < 1500/mm

Thrombopenia

Thrombocytopenia
Thrombosis

Thrombosis

Convincing history of pleuritic pain or rubbing heard by
a physician or evidence of pleural effusion

Pleuritis

Pericarditis: documented by ecg or rub or evidence of
pericardial effusion

Pericarditis

Pleuritis and/or pericarditis: either or both of two above
described

Heart

PLEURITIS and/or PERICARDITIS
Venous clot

Venous clot

Arterial clot

Arterial clot
Any clot

Any clot
Myocard infarction

Myocardio infarction

Valvular disease

Valvular heart disease

Valvular disease site

Aortic, mitral, tricuspid, pulmonic

Numb valvuar

Based on the valvular disease type
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Stroke

Stroke

Avascular necrosis

Avascular necrosis

Pulmonary hypertension ≥40mmhg rvsp

Kidney

Lung

Pulmonary hyperten
Pulmonaru vasc lesion

Pulmonary vascular disease by biopsy or autopsy

Pulmonary fibrosis

Pulmonary fibrosis based on chest xray or ct scan

Evidence of lung disease

Lung disease define by phtn (clin-p1) + and/or
pulmonary fibrosis (clin-p3) +

Evidence of renal disease

Renal disease define by acrrenal + and/or renal biopsy +

Renal cell cast

Renal cellular cast- red, hemoglobin, granular, tubular,
or mixed

Renal proteinuria

Renal proteinuria- persistent > 0.5 grams/24hrs or > 3+

Renal hematuria

Renal hematuria- > 5 rbc per high powered field
Reported renal clot

Renal clot

Reported renal arthery stenosis

Renal artery stenosis

Seizure in the absence of offending drugs or known
metabolic derangements

Neuro

Seizure

Psychosis in the absence of offending drugs or known
metabolic derangements

Psychosis
Neuropathy

Any neuropathy

Neuropsychiatric

Neuropsychiatric

Chorea

Chorea

Glucose

Glucose normal range: 65-99 mg/dl
Urea nitrogen (bun) normal range: 7-25 mg/ml

Ureanitrogen (BUN)

Creatine normal range: 0.5-1.4 mg/dl

Creatine

Serum creatine

Lab tests - Metabolic Panel

Serum creatine

Bun/creatine ratio normal range: 6-25 calc

BUN/Creatine ratio
Sodium

Sodium normal range: 135-146 mmol/l

Potasium

Potasium normal range: 3.5-5.3 mmol/l

Chloride

Chloride normal range: 98-110 mmol/l
Carbon dioxide normal range: 21-33 mmol/l

Carbon dioxide
Calcium

Calcium normal range: 8.5-10.4 mg/dl

Total protein

Total protein normal range: 6-8.3 g/dl

Albumin

Albumin normal range: 3.7-5.1 g/dl

Globulin

Globulin normal range: 2.2-4.2 g/dl
Albumun/globulin normal range: 0.8-2 calc

Albumun/globulin

Bilirubin normal range: 0.2-1.5 mg/dl

Bilirubin

Alkaline phosphatase normal range: 20-125 mg/dl

Alkaline phosphatase
Ast

Ast normal range: 3-35 mg/dl

Alt

Alt normal range: 3-40 u/l
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Creatine kinase normal range: 0-165 u/l

Urinalysis

Creatine kinase
Urine glucose

Urine glucose normal range: 0

Urine protein

Urineprotein normal range: 0

Urine WBC

Urine wbc normal range: </= 5

Urine RBC

Urine rbc normal range: </= 5
Urine squamos eplithelial cells normal range: </= 5

Urine squamos eplithelial cells

Urine bacteria normal range: 0

Lab tests - Hematology

Urine bacteria
Hyaline cast

Hyaline cast normal range: 0

WBC count

Wbc count normal range: 3.8-10.8 thous/mcl

RBC count

Rbc count normal range: 4.20-5.80 mill/mcl

Hemoglobin

Hemoglobin normal range: 13.2-17.1 g/dl

Hematocrit

Hematocrit normal range: 38.5-50%

Mcv

Mcv normal range: 80-100 fl

Mch

Mch normal range: 27-33 pg

Mchc

Mchc normal range: 32-36 g/dl

Rdw

Rdw normal range: 11-15%

Platelet count

Platelet count normal range: 140-400 thous/mcl

Absolute neutrophils

Absolute neutrophils normal range: 1500-7800
cells/mcl

Absolute lymphocytes

Absolute lymphocytes normal range: 850-3900
cells/mcl

Absolute monocytes

Absolute monocytes normal range: 200-950 cells/mcl

Absolute eosinophils

Absolute eosinophils normal range: 15-500 cells/mcl
Absolute basophils normal range: 0-200 cells/mhc

Absolute basophils

Neutrophil % normal range: 35-80%

Neutrophil %

Lymphocyte % normal range: 18-44%

Lymphocyte %
Monocyte %

Monocyte % normal range: 0-10%

Eosinophyl %

Eosinophyl % normal range: 0-3%
Basophils % normal range: 0-1%

Basophils %

Ana

Ana +

Anti-rnp at hemagglutination titer > 1:1600

Lupus Specific lab tests

Anti-RNP +

Sm normal range: 0-20

Anti-Sm Abs +

Dsdna titer normal range: 5-9 iu/ml

Anti-DNA Abs +

Elevated dna if ≥ 10 iu/ml

Dna elevated
FANA titer

Fana titer normal range: <320

Fana_pattr

Fana pattern. Homo , speckled nucleolar,
homo/speckled, mixed , speckled/mixed, no-specific

Ssa_result

Ssa normal range: < 20 eu/ml

Ssb_result

Ssb normal range: < 20 eu/ml

Scl_result

Scl normal range: < 20 eu/ml
Anti-phospholipid abs + if > 10 gpl u/ml

Anti-phospho-lipid Abs +
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Anti cardolipin antibody if > 10 gpl u/ml

Anti cardolipin antibody

Anticardiolipin igg normal ranger: < 10 gpl u/ml

Anticardiolipin igg LEVEL

Anticardiolipin igg + if > 10 gpl u/ml

Anticardiolipin igg +

Anticardiolipin igm normal ranger: < 10 gpl u/ml

Anticardiolipin igm Level

Igm anticrd + if > 10 gpl u/ml

Igm anticrd +

Anticardiolipin iga normal ranger: < 10 gpl u/ml

Anticardiolipin iga LEVEL

Iga anticrd+ if > 10 gpl u/ml

Iga anticrd+

C3 complement normal range: 90 – 180 mg/dl

C3 complement level

C3_low if < 90 mg/dl

C3_low

C4 complement normal range: 16 – 47 mg/dl

C4 complement level

C4_low if < 16

C4_low

Esr nomal ramnge: < 10 mg/dl

Esr

Esr_elevated if >10 mg/dl

Esr_elevated

C reactive protein nomal range: 1.0 mg/dl

C reactive protein
Crp_elevated

Crp_elevated fi . 1.0 mg/dl

RF latex Titer

Rf latex titer normal range: 14 iu/ml

RF ELISA igm Titer

Rf elisa igm titer normal range: < 20 iu/ml

RF ELISA igg Titer

Rf elisa igg titer normal range: < 20 iu/ml
Cpk normal range: < 165 u/l

Cpk level

Cpkeleavted: > 165 u/l

Experimental Lab test

CPK elevated
Baff

Baff normal cytokine level < 1.19 ng/ml
(based on healthy group average + sd of healthy group)

Baffr

Baffr normal cytokine level < 0.09 ng/ml
(based on healthy group average + sd of healthy group)

Taci

Taci normal cytokine level < 0.02 ng/ml
(based on healthy group average + sd of healthy group)

Bcma

Bcma normal cytokine level < 1.64 ng/ml
(based on healthy group average + sd of healthy group)

Ifng

Ifng normal cytokine level < 13.13 pg/ml
(based on healthy group average + sd of healthy group)

Tnfa

Tnfa normal cytokine level < 7.58 pg/ml
(based on healthy group average + sd of healthy group)

Scd40l

Scd40l normal cytokine level < 1959.30 pg/ml
(based on healthy group average + sd of healthy group)

Il12p40

Il12p40 normal cytokine level < 61.68 pg/ml
(based on healthy group average + sd of healthy group)

Il12p70

Il12p70 normal cytokine level < 18.77 pg/ml
(based on healthy group average + sd of healthy group)

Il23

Il23 normal cytokine level < 348.34 pg/ml
(based on healthy group average + sd of healthy group)

Il17a

Il17a normal cytokine level < 3.88 pg/ml
(based on healthy group average + sd of healthy group)

Il17af

Il17af normal cytokine level < 19.40 pg/ml
(based on healthy group average + sd of healthy group)

Il17f

Il17f normal cytokine level < 38.00 pg/ml
(based on healthy group average + sd of healthy group)
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Il21

Il21 normal cytokine level < 13.5 pg/ml
(based on healthy group average + sd of healthy group)

Il22

Il22 normal cytokine level < 31 pg/ml
(based on healthy group average + sd of healthy group)

Il33

Il33 normal cytokine level < 12.3 pg/ml
(based on healthy group average + sd of healthy group)

E-selectin

Eselectin normal cytokine level < 23.63 ng/ml
(based on healthy group average + sd of healthy group)

Ngal

Ngal normal cytokine level < 79.10 ng/ml
(based on healthy group average + sd of healthy group)

Igm anti-U1A (196-203) titer

P1-igm average normal range: 0-100

Igm anti-sme (63-70) titer

P2-igm average normal range: 0-100

Igm anti-smf (46-53) titer

P3-igm average normal range: 0-100

Igm anti-U1C (90-97) titer

P4-igm average normal range: 0-100

Igm anti-U1-70K (337-344) titer

P5-igm average normal range: 0-100

Igm anti-smb (83-90) titer

P6-igm average normal range: 0-100

Igm anti-smg (1-8) titer

P7-igm average normal range: 0-100

Igm anti-smd3 (20-27) titer

P8-igm average normal range: 0-100

Igm anti-smf (77-84) titer

P9-igm average normal range: 0-100

Igm anti-U1A (112-119) titer

P10-igm average normal range: 0-100

Igm anti-smd2 (14-21) titer

P11-igm average normal range: 0-100

Igm anti-smd1 (22-29) titer

P12-igm average normal range: 0-100

Igm anti-U1A (178-185) titer

P13-igm average normal range: 0-100

Igm anti-U1-70K (325-332) titer

P14-igm average normal range: 0-100

Igm anti-U1C (66-73) titer

P15-igm average normal range: 0-100

ELISA anti-snrnp

Based on healthy group average + sd of healthy group

Immunoblot anti-70KD

Based on healthy group average + sd of healthy group

Immunoblot anti-Sm

Based on healthy group average + sd of healthy group

Immunoblot anti-U1-A

Based on healthy group average + sd of healthy group
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APPENDIX 4
Biological system

Variable
Telangiectasia
Nasal ulcers
Oral ulcers
Hist hand swelling
Obs hand swelling
Sclerodactyly
Pitting

SKIN

Alopecia
Rash
Photosensitivity

CLINICAL MANIFESTATIONS

Discoid rash
Raynaud's
Calcinosis
Prox sclerodema
Sicca
Myositis
Myalgia
Arthralgia
Hist prox muscle weakness

MUSCLE

Obs prox muscle weakness
Hist hand swelling
Obs hand swelling
Low extremety swelling
Facial swelling
Morning stiff
Tender
Synovitys
Hist swelling

JOINTS

Obs swelling
Swelling (>3)
Symmetric sweeling
Pain
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Deformity
Any lymphadenopathy
Swelling

LYMPH
NODES

Neck swelling
Axila swelling
Groin swelling
Rheumatoid nodule

GASTRO

Gastric reflux
Anemia
Hemolytic anemia
Leukopenia

BLOOD

Lymphopenia
Thrombopenia
Thrombosis
Pericarditis
Pleuritis
Pericarditis/pleuritis
Any clot

HEART

Venous clot
Valvular disease
Avascular necrosis
Myocardial infarction
Stroke
Hypertension
Vascular lesions

LUNG

Fibrosis
Lung disease
Proteinuria
Hematuria
Clot

KIDNEY

Artherial stenosis
Cell cast
Renal disease
Neuropathy

NERVOUS

Psychosis
Chorea

125

APPENDIX 4, continuation

Lab tests

Variable

URINALYSIS

Glucose +
Protein +
Wbc +
Rbc +
Squamos eplithelial cells +
Hyaline cast +
Sm level
Sm +
Dsdna titer
Dna +
DNA elevated

Fana +

TRADITIONAL FOR LUPUS

LABORATORY TESTS

FANA titer

Ssa +
C3 level
C3 low
C4 level
C4 low
Esr
ESR elevated
Crp
CRP elevated
Igm-RF ELISA titer
Igm-RF +
Igg-RF ELISA titer
Igg-RF +
CPK level
CPK elevated
Il17a
Igm-U1A ELISA (112-119)

EXPERIMENTAL

Igm-U1A ELISA (196-203)
Igm-smd2 ELISA (14-21)
Igm-smd2 ELISA (14-21)
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